<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cyclophosphamide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cyclophosphamide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cyclophosphamide: Pediatric drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_general" data-topicid="9308" href="/d/html/9308.html" rel="external">see "Cyclophosphamide: Drug information"</a> and <a class="drug drug_patient" data-topicid="12347" href="/d/html/12347.html" rel="external">see "Cyclophosphamide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866472"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Procytox</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1046686"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent</span>;</li>
<li>
<span class="list-set-name">Antineoplastic Agent, Alkylating Agent (Nitrogen Mustard)</span>;</li>
<li>
<span class="list-set-name">Antirheumatic Miscellaneous</span>;</li>
<li>
<span class="list-set-name">Immunosuppressant Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462417"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Antiemetics may be recommended (emetogenic potential varies by dose and combination therapy).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> For oncology uses, details concerning dosing in combination regimens should also be consulted.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2f930c6e-27e7-4ef2-b112-96407f58305c">Neuroblastoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma:</b> Limited data available: <i>INES 99.1 regimen courses 1 and 2:</i> Term neonates: IV: 3.5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172879'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F155487"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Doses IV ≥1,000 mg/m<sup>2</sup> are associated with a high emetic potential and IV doses &lt;1,000 mg/m<sup>2</sup> and all oral doses are associated with a moderate emetic risk; antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-23512831','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-23512831','lexi-content-ref-30729654'])">Ref</a></span>). To lessen potential toxicity with doses for oncologic uses, hydration, and follow-up mesna therapy are typically administered; refer to specific protocol.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>For oncology uses, all dosing presented based on clinically recognized trials; consult specific regimens concerning dosing in combination regimens. In pediatric patients, dosing may be based on either BSA (mg/<b>m<sup>2</sup></b>) or weight (mg/kg); use extra precaution to verify dosing parameters during calculations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Oncologic uses:</i></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e139402c-8504-406e-bb69-fadc6e0aabf5">Acute lymphoblastic leukemia, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, high-risk:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8221579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8221579'])">Ref</a></span>): NYII Protocol:</p>
<p style="text-indent:-2em;margin-left:4em;">Induction: Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> on Day 2 (in combination with steroid, daunorubicin, vincristine, and asparaginase).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance I: Children and Adolescents: IV: 600 mg/<b>m<sup>2</sup></b>on Day 4 (in combination with steroid, mercaptopurine, vincristine, daunorubicin, methotrexate, cytarabine, and thioguanine).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="325fe1c9-065e-450c-9429-246476af14bd">Acute lymphoblastic leukemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia, relapsed/refractory:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hijiya 2011</i>: Children and Adolescents: IV: 440 mg/<b>m<sup>2</sup></b> over 30 to 60 minutes in combination with clofarabine and etoposide; number of doses dependent on phase of protocol: Induction: Days 1 to 5, and Consolidation: Days 1 to 4.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parker 2010</i>: UK-ALL R3 protocol: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Phase 2 Consolidation (weeks 5 to 8): IV: 440 mg/<b>m<sup>2</sup></b> on Days 15 to 19 in combination with steroid, vincristine, methotrexate, PEG-asparaginase, and etoposide.</p>
<p style="text-indent:-2em;margin-left:6em;">Phase 5, before Continuation (weeks 14 to 29): IV: 300 mg/<b>m<sup>2</sup></b> on Days 42, 49, 99, and 106 in combination with steroid, mercaptopurine, vincristine, methotrexate, etoposide, and cytarabine.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3af7be48-9503-48e3-b4fb-fbcfba6a47a9">CNS tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>CNS tumors, malignant (medulloblastoma, PNET, ependymoma, brainstem glioma):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15611503','lexi-content-ref-9440745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15611503','lexi-content-ref-9440745'])">Ref</a></span>): Head Start II Protocol: Infants and Children &lt;10 years: IV: 65 mg/kg on Days 2 and 3 with mesna every 21 days for 5 cycles (in combination with cisplatin, vincristine, etoposide, and high-dose methotrexate; then followed by an auto-transplantation).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c8696d93-f6f4-4866-8db5-8bddfaef0662">Desmoplastic small round cell tumor</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Desmoplastic small round cell tumor (DSRCT):</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622067'])">Ref</a></span>): High-dose cyclophosphamide: HD-CAV/IE regimen: P6 Protocol:</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;10 years: IV: 70 mg/kg over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7.</p>
<p style="text-indent:-2em;margin-left:4em;">Children <i>≥</i>10 years and Adolescents: IV: 2,100 mg/<b>m<sup>2</sup></b>over 6 hours with mesna and hydration on Day 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>VAC/IE regimen:</i> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594313'])">Ref</a></span>): Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> with mesna on Day 1 of a 21-day treatment cycle in combination with vincristine and doxorubicin (then dactinomycin when maximum doxorubicin dose reached), alternate with IE (ifosfamide and etoposide) for a total of 17 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>High-dose cyclophosphamide: HD-</i>
<i>CAV/IE</i>
<i>regimen:</i> P6 Protocol: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622067']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622067'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;10 years: IV: 70 mg/kg over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥10 years and Adolescents: IV: 2,100 mg/<b>m<sup>2</sup></b> over 6 hours with mesna and hydration on Days 1 and 2 of a 21-day treatment cycle in combination with vincristine and doxorubicin for courses 1, 2, 4, and 6, alternate with ifosfamide and etoposide for courses 4, 5, and 7.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP (high-risk):</i> Children and Adolescents: IV: 1,200 mg/<b>m<sup>2</sup></b> on Day 0 of a 21-day treatment cycle for 4 cycles in combination with bleomycin, etoposide, doxorubicin, vincristine, prednisone, and procarbazine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21079154']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21079154'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ABVE-PC </i>
<i>(intermediate-risk</i>): Children and Adolescents: IV: 800 mg/<b>m<sup>2</sup></b> over 1 hour on the first day of a 21-day cycle for up to 4 cycles (depending upon response) in combination with doxorubicin, vincristine, etoposide, prednisone, and bleomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-19584400']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25542311','lexi-content-ref-25311218','lexi-content-ref-19584400'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cab1cfc6-2a86-4e85-8455-d887b4c1ce71">HSCT conditioning; myeloablative transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HSCT conditioning; myeloablative transplant: </b> Limited data available: Infants, Children, and Adolescents: IV: 50 mg/kg/day for 4 days beginning 5 days before transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17272503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17272503'])">Ref</a></span>); other regimens have used 60 mg/kg/day for 2 days following busulfan (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15353481','lexi-content-ref-23489519']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15353481','lexi-content-ref-23489519'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosing adjustment in obese patients</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24462742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24462742'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Cy200 (cyclophosphamide total dose of 200 mg/kg): Use the lesser of ideal body weight (IBW) or actual body weight (ABW).</p>
<p style="text-indent:-2em;margin-left:6em;">Cy120 (cyclophosphamide total dose of 120 mg/kg): Use IBW or ABW until &gt;120% IBW; then use ABW25 for patients &gt;120% IBW.</p>
<p style="text-indent:-2em;margin-left:8em;">ABW25: Adjusted weight (kg) = Ideal body weight (kg) + 0.25 [actual body weight (kg) - ideal body weight (kg)].</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f912072-ddd7-4c2b-936c-772632e6cc62">Neuroblastoma during infancy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma during infancy (unresectable): </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21172879']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21172879'])">Ref</a></span>): INES 99.1 regimen courses 1 and 2:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants:</p>
<p style="text-indent:-2em;margin-left:6em;">&lt;10 kg: IV: 3.5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine.</p>
<p style="text-indent:-2em;margin-left:6em;">≥10 kg: IV: 5 mg/kg on Days 1 to 5 administered at 2-week intervals for 2 cycles initially, in combination with vincristine.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31462046-bab9-4b9c-b2fe-0c15f370f35b">Neuroblastoma; high-risk, newly diagnosed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma</b>
<b>; high-risk, newly diagnosed:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22010014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22010014'])">Ref</a></span>): Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Induction cycles 1 and 2 (21-day cycles):</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤12 kg: IV: 13.3 mg/kg over 30 minutes on Days 1 to 5 (in combination with topotecan) for 2 cycles.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;12 kg: IV: 400 mg/<b>m<sup>2</sup></b>over 30 minutes on Days 1 to 5 (in combination with topotecan) for 2 cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Induction cycles 4 and 6 (21-day cycles):</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≤12 kg: IV: 70 mg/kg over 6 hours with mesna on Days 1 and 2 (in combination with doxorubicin and vincristine).</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &gt;12 kg: IV: 2,100 mg/<b>m<sup>2</sup></b> over 6 hours with mesna on Days 1 and 2 (in combination with doxorubicin and vincristine).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f6fc7672-3ba1-4f98-9c9e-f6cd53c46ea2">Neuroblastoma, relapsed or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuroblastoma, relapsed or refractory:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20564411','lexi-content-ref-20934323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20564411','lexi-content-ref-20934323'])">Ref</a></span>): HD-CCV or HD-CTV regimen: Infants and Children ≤10 years: IV: 70 mg/kg on Days 1 and 2 (in combination with irinotecan and vincristine or in combination with topotecan and vincristine).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ac1551d4-0bff-4d8a-8de4-b0eed5c04298">Non-Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma: </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">COP regimen: Reduction: Infants ≥6 months, Children, and Adolescents: IV: 300 mg/<b>m<sup>2</sup></b>over 15 minutes on Day 1 (in combination with vincristine and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">COPADM 1 regimen: Induction 1: Infants ≥6 months, Children, and Adolescents: IV: 250 mg/<b>m<sup>2</sup></b>/dose over 15 minutes every 12 hours on Days 2 to 4 (6 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629','lexi-content-ref-17132719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629','lexi-content-ref-17132719'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">COPADM 2 regimen: Induction 2: Infants ≥6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose over 15 minutes every 12 hours on Days 2 to 4 (6 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate, +/- Rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">COPADM regimen: Maintenance 1: High-risk patients: Infants ≥6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b> over 15 minutes on Days 2 and 3 (2 doses) (in combination with doxorubicin, vincristine, prednisone, methotrexate) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">COPA regimen: Maintenance course 3: High-risk patients: Infants ≥6 months, Children, and Adolescents: IV: 500 mg/<b>m<sup>2</sup></b>/dose over 30 minutes on the first 2 days of the cycle (2 doses) (in combination with doxorubicin, vincristine, prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17138821','lexi-content-ref-22940833','lexi-content-ref-25066629'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9ec4d87-730c-433d-a432-c55ed2d92715">Non-Hodgkin lymphoma, T-cell or anaplastic large cell lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphoma, T-cell or anaplastic large cell lymphoma (ALCL)</b>: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8164040','lexi-content-ref-11389005']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8164040','lexi-content-ref-11389005'])">Ref</a></span>): NHL-BFM90 protocol: Infants, Children, and Adolescents: IV: 200 mg/<b>m<sup>2</sup></b>over 1 hour; number of doses, days of administration, and other chemotherapy combinations are dependent on protocol specific phase.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99c12c7b-a58c-48f3-9fb0-f789af7683c2">Palliative intent chemotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Palliative intent chemotherapy (metronomic therapy):</b> Limited data available: Infants, Children, and Adolescents: Oral: 2.5 mg/kg once daily, maximum dose: 100 mg/dose for 21 days, alternating with a 21-day cycle of etoposide in combination with continuous thalidomide, celecoxib, and fenofibrate therapy; in the trial, the youngest patient reported was 191 days old (around 6 months of age) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24123865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24123865'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="dc5b95eb-c882-4525-9ef3-0ecbf274d47c">Post-transplant lymphoproliferative disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Post-transplant lymphoproliferative disease (PTLD):</b> Limited data available: Infants, Children, and Adolescents: IV: 600 mg/<b>m<sup>2</sup></b> on Day 1 every 21 days for 6 cycles in combination with prednisone (all 6 cycles) and rituximab (first 2 cycles only); the youngest patient included in the reported experience was 0.8 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22883417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22883417'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="99f6fc92-5e20-46c5-a7d9-0504aaf1e363">Retinoblastoma, extraocular</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Retinoblastoma, extraocular:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12518344']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12518344'])">Ref</a></span>): Protocol 94 regimen: Children: IV: 65 mg/kg over 1 hour on Day 1 with mesna of a 21-day treatment cycle (in combination with idarubicin and vincristine) alternating cycles with carboplatin and etoposide for a total of 8 cycles.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Low risk: </i>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25267746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25267746'])">Ref</a></span>): VAC regimen: Doses were administered with hydration and mesna every 21 days for 4 doses of a 22-week cycle in combination with vincristine and dactinomycin.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants and Children &lt;3 years: IV: 40 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥3 years and Adolescents: 1,200 mg/<b>m<sup>2</sup></b>.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Intermediate risk</i>: Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19770373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19770373'])">Ref</a></span>): VAC regimen: Doses were administered with hydration and mesna every 21 days for 14 cycles in combination with vincristine and dactinomycin.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants: IV: 36 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 1 to 3 years: IV: 73 mg/kg.</p>
<p style="text-indent:-2em;margin-left:6em;">Children <i>&gt;</i>3 years: 2,200 mg/<b>m<sup>2</sup></b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf8deca5-6239-4ae6-a591-0a3dedc917e8">Wilms tumor, anaplastic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor, anaplastic (stage II to IV): </b>Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7931483']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7931483'])">Ref</a></span>): National Wilms’ Tumor Study (NWTS) protocol 4 regimen J: Children and Adolescents &lt;16 years: IV: 10 mg/kg on Days 1 to 3 (3 doses) every 6 weeks (in combination with vincristine, dactinomycin, and doxorubicin).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33321132-9b42-4496-ab22-eee8b2d8f8c5">Wilms tumor, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Wilms tumor, relapsed/refractory: </b>Limited data available: National Wilms’ Tumor Study (NWTS) protocol-5 regimen:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children weighing ≤30 kg: IV: 14.7 mg/kg with mesna; reported frequency and combination chemotherapy variable, refer to specific protocols. One regimen alternated the frequency based on week of therapy: Weeks 3, 9, 15, and 21: Doses administered once daily for 5 days (in combination with etoposide); Weeks 6, 12, 18, and 24 administered once daily for 3 days (in combination with doxorubicin and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547940'])">Ref</a></span>); another protocol administered for 5 days, on Weeks 0 and 3 in combination with etoposide; alternate with carboplatin and etoposide on Weeks 6 and 9 and continued for 90 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17539021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17539021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &gt;30 kg and Adolescents &lt;16 years at diagnosis: IV: 440 mg/<b>m<sup>2 </sup></b>with mesna; reported frequency and combination chemotherapy variable, refer to specific protocols. One regimen alternated the frequency based on week of therapy: Weeks 3, 9, 15, and 21: Doses administered once daily for 5 days (in combination with etoposide); Weeks 6, 12, 18, and 24 administered once daily for 3 days (in combination with doxorubicin and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16547940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16547940'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Non-Oncologic uses:</i></p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27ac4b8b-309d-4265-9d7e-190fd154531f">Aplastic anemia, severe, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aplastic anemia, severe, refractory:</b> Limited data available: Children and Adolescents ≥2 years: High-dose therapy: IV: 45 to 50 mg/kg/day for 4 days has been used in several small trials; concurrent prophylactic antimicrobial therapy should be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19827142','lexi-content-ref-8555470','lexi-content-ref-20018919','lexi-content-ref-21358440','lexi-content-ref-Jaime-Perez.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19827142','lexi-content-ref-8555470','lexi-content-ref-20018919','lexi-content-ref-21358440','lexi-content-ref-Jaime-Perez.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0ac2ebd5-754c-4d5e-9866-5b6da57d716a">Kawasaki Disease; refractory to multiple therapies</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Kawasaki Disease; refractory to multiple therapies:</b> Very limited data available: Infants and Young Children: IV: 2 mg/kg/dose once daily; some have suggested a gradual taper over 1.5 to 7 months; however, details of taper have not been described. Dosing based on a retrospective study of patients with refractory Kawasaki Disease that included two patients (ages 2.7 and 9 years) who had failed to respond to 3 doses of IVIG and required high-dose IV methylprednisolone; after initiation of cyclophosphamide, steroids were able to be successfully tapered and final ECHO showed resolution of aneurysm. While taper schedule was not described, both patients were discharged on a taper over 1.5 to 7 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28356445','lexi-content-ref-10835091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28356445','lexi-content-ref-10835091'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65d2ea53-b01d-480b-b7db-288a7bfc19bc">Lupus nephritis, proliferative</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis, proliferative:</b> Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial phase; pulse therapy:</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">6-month course: Usual range: 500 to 1,000 mg/<b>m<sup>2</sup></b>/dose once monthly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012'])">Ref</a></span>); the following regimen has been used for dosage escalation: Initial: 500 mg/<b>m<sup>2</sup></b> then titrate as tolerated every 4 weeks in 250 mg/<b>m<sup>2</sup></b> increments up to 750 or 1,000 mg/<b>m<sup>2</sup></b> every month; maximum monthly dose: 1,500 mg/month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851469','lexi-content-ref-22162255']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851469','lexi-content-ref-22162255'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">3-month course: 500 mg every 2 weeks for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851469','lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851469','lexi-content-ref-KDIGO.2012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 1 to 1.5 mg/kg/day for 2 to 4 months; maximum daily dose: 150 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012'])">Ref</a></span>); higher doses (2 to 2.5 mg/kg/day for 3 months) may be required in patients with worsening prognostic factors (eg, acute renal function deterioration) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22851469']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22851469'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance phase: IV: 500 to 1,000 mg/<b>m<sup>2</sup></b> every 3 months for a total of 1.5 to 3 years has been used; however, current guidelines recommend other oral immunosuppressive agents for maintenance therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-KDIGO.2012','lexi-content-ref-Kliegman.1','lexi-content-ref-10657833']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-KDIGO.2012','lexi-content-ref-Kliegman.1','lexi-content-ref-10657833'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c482915-3cac-49e9-b7f5-baaa3eb54c8f">Nephrotic syndrome, minimal change</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotic syndrome, minimal change (frequently relapsing):</b> Infants, Children, and Adolescents: Oral: 2 mg/kg/day for 8 to 12 weeks; reported range: 2 to 3 mg/kg/day; maximum cumulative dose: 168 mg/kg; dosing based on ideal bodyweight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19651590','lexi-content-ref-KDIGO.2012','lexi-content-ref-23871408']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19651590','lexi-content-ref-KDIGO.2012','lexi-content-ref-23871408'])">Ref</a></span>). Treatment beyond 90 days may increase the potential for sterility in males.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="76dd4318-a118-4f56-a0f3-61b386a04957">Uveitis, severe; recalcitrant, high-risk vision loss</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Uveitis, severe; recalcitrant, high-risk vision loss:</b> Limited data available: Children and Adolescents: Oral: Initial: 2 mg/kg/day once daily; usual reported range: 1 to 3 mg/kg/day in combination with corticosteroids (which may be decreased while on cyclophosphamide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11024423','lexi-content-ref-19969366','lexi-content-ref-20553975']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11024423','lexi-content-ref-19969366','lexi-content-ref-20553975'])">Ref</a></span>); dosing based on large, multicenter report of 215 patients with ocular inflammatory disease which included 44 patients with uveitis (age range: 11.5 to 76.4 years); after 12 months of therapy ~89% of patients had no inflammatory disease activity or only slightly active disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19969366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19969366'])">Ref</a></span>). <b>Note:</b> Some data suggests that pulse intravenous therapy may be less effective than oral cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19969366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19969366'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="36beb3fc-5453-402c-879e-4ab10222b4cf">Vasculitis, ANCA-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vasculitis, ANCA-associated (eg, granulomatosis with polyangiitis [GPA], Wegener granulomatosis):</b> Limited data available: Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Initial: 15 mg/kg every 2 weeks for 3 doses, then 15 mg/kg every 3 weeks until remission or azathioprine maintenance; dosing based on experience from a pediatric case series (n=5) and a larger adult trial (n=76); in the pediatric case series, the median cumulative dose was 90 mg/kg (range: 63 to 115 mg/kg), most patients received 6 to 7 pulses of therapy; in the adult trial, therapy was continued for 3 months after remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451574','lexi-content-ref-22541686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451574','lexi-content-ref-22541686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: 2 mg/kg/day in combination with corticosteroids until remission; a subsequent decrease in dose to 1.5 mg/kg/day for another 3 months has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451574','lexi-content-ref-Kliegman.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451574','lexi-content-ref-Kliegman.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hematologic toxicity: </i>May require dose reduction or treatment interruption.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hemorrhagic cystitis, severe: </i>Discontinue treatment.</p></div>
<div class="block dorp drugH1Div" id="F51090475"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; decreased renal excretion of cyclophosphamide and its metabolites may occur; monitor patients with severe impairment (CrCl 10 to 24 mL/minute) for signs and symptoms of toxicity. The following guidelines have been used by some clinicians:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Aronoff 2007:</i> Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl ≥10 mL/minute: No dosage adjustment required.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;10 mL/minute: Administer 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Hemodialysis: Moderately dialyzable (20% to 50%); administer 50% of normal dose; administer after hemodialysis.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous ambulatory peritoneal dialysis (CAPD): Administer 75% of normal dose.</p>
<p style="text-indent:-2em;margin-left:8em;">Continuous renal replacement therapy (CRRT): Administer 100% of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>KDIGO 2012:</i>
<b>Lupus nephritis:</b> Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 25 to 50 mL/minute: Administer 80% of normal dose.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl 10 to &lt;25 mL/minute: Administer 70% of normal dose.</p></div>
<div class="block dohp drugH1Div" id="F51090476"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling; in severe hepatic impairment, conversion to an active metabolite may be reduced potentially affecting efficacy. The half-life and clearance of cyclophosphamide metabolites may be increased/decreased respectively.</p>
<p style="text-indent:-2em;margin-left:4em;">The following adjustments have been recommended with oncologic uses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16473644']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16473644'])">Ref</a></span>): All patients:</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 3.1 to 5 mg/dL or transaminases &gt;3 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin &gt;5 mg/mL: Avoid use.</p></div>
<div class="block doa drugH1Div" id="F155460"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9308" href="/d/html/9308.html" rel="external">see "Cyclophosphamide: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Cyclophosphamide is associated with a moderate to high emetic potential (depending on dose, regimen, or administration route); antiemetics are recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>). Increased hydration and frequent voiding are recommended to help prevent cystitis; some protocols utilize mesna to prevent bladder toxicity/hemorrhagic cystitis (refer to protocol). May require dose reduction or treatment interruption based on clinical response and hematologic toxicity (eg, ANC &lt;1,500 mm<sup>3</sup>). Antimicrobial prophylaxis may be considered in appropriate patients. Consider growth factors (primary or secondary prophylaxis) in patients at increased risk for complications due to neutropenia. Patient should be under the care of a clinician experienced with using cyclophosphamide.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3b5fd58c-2ade-43ce-a3f5-be85a60e433f">Acute lymphoblastic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute lymphoblastic leukemia (off-label dosing): Multiple-agent regimens:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB 10403 regimen: </i>Patients &lt;40 years of age: <b>IV:</b> Remission consolidation phase (course 2): 1,000 mg/m<sup>2</sup> on days 1 and 29; Delayed intensification phase: 1,000 mg/m<sup>2</sup> on day 29; phases are part of combination chemotherapy; refer to protocol for details (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30658992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30658992'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Hyper-CVAD regimen:</i>
<b>IV:</b> 300 mg/m<sup>2</sup> over 3 hours every 12 hours for 6 doses on days 1, 2, and 3 (in combination with mesna, vincristine, doxorubicin, and dexamethasone) during odd-numbered cycles (cycles 1, 3, 5, 7) of an 8-cycle phase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10653870']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10653870'])">Ref</a></span>); plus a BCR-ABL tyrosine kinase inhibitor (for Philadelphia chromosome-positive disease) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20466853','lexi-content-ref-14551133']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20466853','lexi-content-ref-14551133'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CALGB8811 regimen:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Adults &lt;60 years of age: <b>IV: </b>Induction phase: 1,200 mg/m<sup>2</sup> on day 1 of a 4-week cycle; Early intensification phase: 1,000 mg/m<sup>2</sup> on day 1 of a 4-week cycle (repeat once); Late intensification phase: 1,000 mg/m<sup>2</sup> on day 29 of an 8-week cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults ≥60 years of age: <b>IV: </b>Induction phase: 800 mg/m<sup>2</sup> on day 1 of a 4-week cycle; Early intensification phase: 1,000 mg/m<sup>2</sup> on day 1 of a 4-week cycle (repeat once); Late intensification phase: 1,000 mg/m<sup>2</sup> on day 29 of an 8-week cycle (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7718875']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7718875'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAALL 2003 regimen:</i> Patients &lt;60 years of age: <b>IV: </b>Induction phase: 750 mg/m<sup>2</sup> on day 1; then 750 mg/m<sup>2</sup> on day 15 (in good early responders) or 500 mg/m<sup>2</sup> every 12 hours for 4 doses on days 15 and 16 (in poor early responders); Consolidation phase: 500 mg/m<sup>2</sup> on days 29 and 30 of consolidation blocks 3, 6, and 9; Late intensification phase: 500 mg/m<sup>2</sup> every 12 hours on day 15; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19124805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19124805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>GRAALL 2005 regimen:</i> Patients &lt;60 years of age: <b>IV: </b>Induction phase: 750 mg/m<sup>2</sup> on day 1; then 750 mg/m<sup>2</sup> on day 15 <b>or</b> 300 mg/m<sup>2</sup> every 12 hours for 6 doses on days 15 to 17; First, second, and third consolidation phases (block 3, block 6, and block 9, respectively): 500 mg/m<sup>2</sup> on days 29 and 30; Late intensification phase (if complete response after first course): 750 mg/m<sup>2</sup> on day 1; then 750 mg/m<sup>2</sup> on day 15 <b>or</b> 300 mg/m<sup>2</sup> every 12 hours for 6 doses on days 15 to 17; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29863974']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29863974'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>MRC UKALL XII/ECOG E2993 regimen:</i> Patients &lt;60 years of age: <b>IV: </b>Induction (phase 2): 650 mg/m<sup>2</sup> on days 1, 15, and 29; Consolidation phase (cycle 3): 650 mg/m<sup>2</sup> on day 29; phases are part of combination chemotherapy; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16105981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16105981'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a881e1b5-4635-4167-8c83-7c4811057163">Adult T-cell leukemia/lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Adult T-cell leukemia/lymphoma (off-label dosing): IV:</b> 350 mg/m<sup>2</sup> on day 1 every 28 days (as part of the VCAP-AMP-VECP multiagent chemotherapy regimen) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17968021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17968021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d7bb5f28-a55f-4d85-8e77-9780520ca80d">Anti-glomerular basement membrane disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anti-glomerular basement membrane disease (anti-GBM or Goodpasture disease) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in combination with glucocorticoids and plasmapheresis in patients with kidney involvement who do not require immediate dialysis, <b>or</b> in patients with pulmonary hemorrhage regardless of kidney involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaplan.1','lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaplan.1','lexi-content-ref-KDIGO.2012'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27267459','lexi-content-ref-Kaplan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27267459','lexi-content-ref-Kaplan.1'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaplan.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaplan.1'])">Ref</a></span>). On plasmapheresis days, administer cyclophosphamide after plasmapheresis. Discontinue therapy after 2 to 3 months; some experts continue therapy for up to 6 months if anti-GBM antibodies are not substantially reduced within 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27267459','lexi-content-ref-Kaplan.1','lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27267459','lexi-content-ref-Kaplan.1','lexi-content-ref-KDIGO.2012'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f629398a-17b2-4a1a-8177-10deeef034f4">Breast cancer</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Breast cancer (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>AC regimen:</i>
<b>IV:</b> 600 mg/m<sup>2</sup> on day 1 every 21 days (in combination with doxorubicin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2202791']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2202791'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CEF regimen:</i>
<b>Oral:</b> 75 mg/m<sup>2</sup>/day days 1 to 14 every 28 days (in combination with epirubicin and fluorouracil) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9704715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9704715'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CMF regimen: </i>
<b>Oral:</b> 100 mg/m<sup>2</sup>/day days 1 to 14 every 28 days (in combination with methotrexate and fluorouracil) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9704715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9704715'])">Ref</a></span>) <b>or</b> IV: 600 mg/m<sup>2</sup> on day 1 every 21 days (in combination with methotrexate and fluorouracil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9653488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9653488'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c69934ce-0797-4220-8bf3-6290b0af6f83">Castleman disease, idiopathic, multicentric</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Castleman disease, idiopathic, multicentric (off-label use; based on limited data): Note:</b> Cyclophosphamide-containing combination chemotherapy regimens (± rituximab) may benefit certain patients with severe idiopathic multicentric Castleman disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30181172']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30181172'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CHOP regimen: </i>
<b>IV:</b> 750 mg/m<sup>2</sup> on day 1 every 3 weeks for 4 cycles (in combination with doxorubicin, vincristine, and prednisone ± rituximab) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19707509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19707509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>TCP regimen:</i>
<b>Oral:</b> 300 mg/m<sup>2</sup> once weekly on days 1, 8, 15, and 22 every 4 weeks (in combination with thalidomide and prednisone). TCP was administered for 2 years or until treatment failure; cyclophosphamide and prednisone were administered for 1 year, while thalidomide was administered for 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30760451']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30760451'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1c2daff1-da41-460d-97f5-616d486189ba">Chronic lymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic lymphocytic leukemia (off-label dosing):</b>
<b>IV:</b> R-FC regimen: 250 mg/m<sup>2</sup>/day for 3 days every 28 days (in combination with rituximab and fludarabine) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20194844']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20194844'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="abae66fe-387f-4e84-acb1-28fe0951cafe">Dermatomyositis/Polymyositis, severe, life-threatening or refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatomyositis/polymyositis, severe, life-threatening or refractory (adjunctive agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as an adjunct to glucocorticoids and other immunosuppressive agents in patients with severe disease that is refractory to other preferred therapies, <b>or</b> as part of initial combination therapy in patients with impending respiratory failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dellaripa.1','lexi-content-ref-Targoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dellaripa.1','lexi-content-ref-Targoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>500 to 750 mg/m<sup>2</sup> every 4 weeks; maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1.5 to 2 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21740984']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21740984'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>Continue therapy for up to 6 months, then transition to an alternative immunosuppressive agent to maintain remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Dellaripa.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Dellaripa.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="18e6e26c-d8fa-42b9-8a6b-e440bcbad715">Eosinophilic granulomatosis with polyangiitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in combination with glucocorticoids to initiate disease remission in patients with severe, multiorgan disease <b>or</b> severe cardiovascular or CNS involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-18413444','lexi-content-ref-King.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-18413444','lexi-content-ref-King.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>600 mg/m<sup>2</sup> once every month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17471546','lexi-content-ref-9448590','lexi-content-ref-7488285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17471546','lexi-content-ref-9448590','lexi-content-ref-7488285'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 mg/kg once daily (maximum: 200 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18413444','lexi-content-ref-9448590','lexi-content-ref-1676753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18413444','lexi-content-ref-9448590','lexi-content-ref-1676753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>Continue therapy for 6 to 12 months, then transition to an alternative immunosuppressive agent to maintain remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17471546','lexi-content-ref-18413444','lexi-content-ref-1676753','lexi-content-ref-King.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17471546','lexi-content-ref-18413444','lexi-content-ref-1676753','lexi-content-ref-King.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aee220af-0844-4780-b143-cde0d52e0c13">Ewing sarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ewing sarcoma (off-label use):</b> VAC/IE regimen: VAC: <b>IV: </b>1,200 mg/m<sup>2</sup> (plus mesna) on day 1 of a 21-day treatment cycle (in combination with vincristine and doxorubicin [then dactinomycin when maximum doxorubicin dose reached]), alternates with IE (ifosfamide and etoposide) for a total of 17 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12594313']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12594313'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49fe01c0-c897-41b4-a63d-329062417bc6">Gestational trophoblastic neoplasia, high-risk</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gestational trophoblastic neoplasia, high-risk (off-label use):</b> EMA/CO regimen: <b>IV: </b>600 mg/m<sup>2</sup> on day 8 of 2-week treatment cycle (in combination with etoposide, methotrexate, leucovorin, dactinomycin, and vincristine), continue for at least 2 treatment cycles after a normal hCG level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14675675','lexi-content-ref-17086804']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14675675','lexi-content-ref-17086804'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="483a0a44-4b60-4f2f-83af-05b9acbc1fad">Graft-versus-host disease, acute and chronic, prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Graft-versus-host disease, acute and chronic, prophylaxis (off-label use): IV:</b> 50 mg/kg on days +3 and +4 following allogeneic blood or marrow transplantation (in combination with mesna) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25267759','lexi-content-ref-25316679','lexi-content-ref-20124511']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25267759','lexi-content-ref-25316679','lexi-content-ref-20124511'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b3dbb31e-e98a-447f-8772-94a38a046c5c">Granulomatosis with polyangiitis and microscopic polyangiitis, organ- or life-threatening</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Granulomatosis with polyangiitis and microscopic polyangiitis, organ- or life-threatening (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>15 mg/kg (maximum: 1,200 mg) once every 2 weeks for 3 doses, followed by 15 mg/kg (maximum: 1,200 mg) once every 3 weeks for 3 to 6 months. Use in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451574','lexi-content-ref-22128076']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451574','lexi-content-ref-22128076'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1.5 to 2 mg/kg/day (maximum: 200 mg/day) in combination with glucocorticoids until remission is induced (usually within 3 to 6 months) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451574','lexi-content-ref-12840090','lexi-content-ref-20647199']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451574','lexi-content-ref-12840090','lexi-content-ref-20647199'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>Transition to an alternative immunosuppressive agent to maintain remission; consider alternative induction therapy if remission is not attained after 3 to 6 months of cyclophosphamide therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34235894','lexi-content-ref-18413444','lexi-content-ref-Falk.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34235894','lexi-content-ref-18413444','lexi-content-ref-Falk.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5c81d47-e10f-457b-9542-080d4f6f1f55">Hematopoietic cell or marrow transplant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hematopoietic cell or marrow transplant (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Conditioning regimens:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Nonmyeloablative transplant (allogeneic):</i>
<b>IV:</b> 750 mg/m<sup>2</sup>/day for 3 days beginning 5 days prior to transplant (in combination with fludarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18411419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18411419'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Myeloablative transplant: </i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">100 mg/kg (based on ideal body weight [IBW], unless actual weight &lt;95% of IBW) as a single dose 2 days prior to transplant (in combination with total body irradiation and etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18256325']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18256325'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">50 mg/kg/day for 4 days beginning 5 days before transplant (with or without antithymocyte globulin [equine]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17272503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17272503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">50 mg/kg/day for 4 days beginning 5 days prior to transplant (in combination with busulfan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8426209','lexi-content-ref-9834301']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8426209','lexi-content-ref-9834301'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">60 mg/kg/day for 2 days (in combination with busulfan and total body irradiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8558201']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8558201'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">60 mg/kg/day for 2 days beginning 4 days prior to transplant (in combination with busulfan) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3311203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3311203'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">1,800 mg/m<sup>2</sup>/day for 4 days beginning 7 days prior to transplant (in combination with etoposide and carmustine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1919637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1919637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Reduced-intensity conditioning regimens: </i>
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:8em;">30 mg/kg/day for 2 days beginning 4 days prior to transplant (in combination with thiotepa and fludarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11756155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11756155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">50 mg/kg/day for 4 days beginning 5 days prior to transplant (in combination with antithymocyte globulin [equine]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9160700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9160700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hematopoietic cell mobilization: IV: </b>1,500 mg/m<sup>2</sup>/day to 2,000 mg/m<sup>2</sup>/day for 2 days on days 1 and 2 (in combination with mesna and G-CSF [filgrastim]) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22248715']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22248715'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="27e021a7-5ca5-4246-a732-eef1337a6f18">Hodgkin lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hodgkin lymphoma (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP regimen:</i>
<b>IV:</b> 650 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and prednisone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12802024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12802024'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>BEACOPP escalated regimen:</i>
<b>IV: </b>1,200 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with bleomycin, etoposide, doxorubicin, vincristine, procarbazine, and prednisone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12802024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12802024'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54622869-0b52-4384-82b8-98d08e40e38b">Interstitial pneumonia, nonspecific, refractory or rapidly progressive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Interstitial pneumonia, nonspecific, refractory or rapidly progressive (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (preferred route): </b>600 mg/m<sup>2</sup> once every month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20560293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20560293'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>). Use in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20560293','lexi-content-ref-Flaherty.1','lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20560293','lexi-content-ref-Flaherty.1','lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>1 to 2 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15738299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15738299'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>). Use in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15738299','lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15738299','lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>Continue therapy for at least 3 to 6 months to determine efficacy; discontinue therapy or transition to an alternative immunosuppressive agent after 6 to 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20560293','lexi-content-ref-Flaherty.1','lexi-content-ref-15738299']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20560293','lexi-content-ref-Flaherty.1','lexi-content-ref-15738299'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc4a4229-ac4b-4d07-8dd1-a42a2ff5a902">Lupus nephritis, focal or diffuse</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lupus nephritis, focal or diffuse (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (shorter, low-dose regimen; preferred regimen): </b>500 mg once every 2 weeks for 6 doses, then transition to an alternative immunosuppressive agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106','lexi-content-ref-32220834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106','lexi-content-ref-32220834'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (longer, high-dose regimen): </b>500 to 1,000 mg/m<sup>2 </sup>once every month for 6 doses, then transition to an alternative immunosuppressive agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556106','lexi-content-ref-32220834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556106','lexi-content-ref-32220834'])">Ref</a></span>). Maximum dose has not been established; some experts do not exceed 1,000 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Falk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Falk.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 1 to 1.5 mg/kg once daily; some experts increase by 0.5 mg/kg/day every week up to 2 mg/kg once daily if needed based on response, and do not exceed 150 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27821390','lexi-content-ref-Falk.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27821390','lexi-content-ref-Falk.1'])">Ref</a></span>). Continue therapy for 2 to 4 months once the dose is stabilized, then transition to an alternative immunosuppressive agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27821390']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27821390'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="220e7cd8-9c58-4b08-8248-a4212d14000c">Lymphodepleting therapy prior to chimeric antigen receptor T-cell immunotherapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lymphodepleting therapy prior to chimeric antigen receptor T-cell immunotherapy (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to axicabtagene ciloleucel: </i>
<b>IV: </b>500 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine) beginning 5 days (on days −5, −4, and −3) prior to chimeric antigen receptor (CAR) T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30518502','lexi-content-ref-34891224','lexi-content-ref-29226797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30518502','lexi-content-ref-34891224','lexi-content-ref-29226797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to brexucabtagene autoleucel:</i>
<b> IV: </b>500 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine; for relapsed/refractory mantle cell lymphoma) beginning 5 days (on days −5, −4, and −3) prior to CAR T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32242358']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32242358'])">Ref</a></span>) <b>or</b> 900 mg/m<sup>2 </sup>once beginning 2 days (on day −2) prior to CAR T-cell infusion on day 0 (in combination with fludarabine; for relapsed/refractory B-cell precursor acute lymphoblastic leukemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34097852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34097852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to ciltacabtagene autoleucel: </i>
<b>IV: </b>300 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine) followed 2 to 4 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34175021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34175021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to idecabtagene vicleucel: </i>
<b>IV: </b>300 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine) beginning 5 days (on days -5, -4, and -3) prior to CAR T-cell infusion on day 0 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33626253']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33626253'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to lisocabtagene maraleucel: </i>
<b>IV: </b>300 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine) followed 2 to 7 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32888407']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32888407'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prior to tisagenlecleucel</i>
<i>:</i>
<b>IV: </b>250 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine; for relapsed/refractory diffuse large B-cell lymphoma) followed 2 to 11 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501490']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501490'])">Ref</a></span>) <b>or</b> 500 mg/m<sup>2</sup>/day for 2 days (in combination with fludarabine; for relapsed/refractory B-cell acute lymphoblastic leukemia) followed 2 to 14 days later by CAR T-cell infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29385370']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29385370'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9fac0539-9bc0-4b45-b605-50bc1ef290c1">Membranous nephropathy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Membranous nephropathy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in combination with glucocorticoids to initiate disease remission in patients at high or very high risk of disease progression, regardless of the presence of lupus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30665568']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30665568'])">Ref</a></span>). Some experts also use cyclophosphamide (in combination with glucocorticoids) as an alternative to other immunosuppressive therapies in patients at moderate risk of disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeVriese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeVriese.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, cyclical (preferred): </b>2 mg/kg once daily during months 2, 4, and 6 (alternating with glucocorticoid therapy during months 1, 3, and 5) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33166580','lexi-content-ref-17494881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33166580','lexi-content-ref-17494881'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeVriese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeVriese.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral, continuous: </b>1.5 to 2 mg/kg once daily for 12 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14993502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14993502'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day, and also limit the total cumulative dose to 25 g to reduce the risk of malignancy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-DeVriese.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-DeVriese.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6402e3f0-529b-4535-9c41-7e49e14d9e66">Merkel cell carcinoma, advanced or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, advanced or recurrent (off-label use; based on limited data): IV:</b> CAV regimen: 1,000 mg/m<sup>2</sup> on day 1 every 21 days (in combination with doxorubicin and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9307187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9307187'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c33ef22-65ff-4e79-9241-9bbe2290b881">Minimal change disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Minimal change disease (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with frequently relapsing or glucocorticoid-dependent disease, regardless of the presence of lupus nephritis. Initiate cyclophosphamide after remission is induced by glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30665569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30665569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 to 2.5 mg/kg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8941578','lexi-content-ref-8159300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8941578','lexi-content-ref-8159300'])">Ref</a></span>); some experts continue therapy for 12 weeks, and do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1','lexi-content-ref-17699450']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1','lexi-content-ref-17699450'])">Ref</a></span>). Gradually taper and discontinue glucocorticoids during cyclophosphamide therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8941578','lexi-content-ref-8159300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8941578','lexi-content-ref-8159300'])">Ref</a></span>). <b>Note: </b>Avoid prolonged (&gt;12 weeks) or repeat courses of cyclophosphamide to reduce the risk of adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyrier.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyrier.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b29b789c-4541-4c71-bb1a-042d051defe9">Mixed cryoglobulinemia syndrome, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Mixed cryoglobulinemia syndrome, moderate to severe (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use as an alternative to rituximab, in combination with glucocorticoids, to induce disease remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fervenza.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fervenza.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>750 mg/m<sup>2</sup> once every month for 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16079934','lexi-content-ref-Fervenza.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16079934','lexi-content-ref-Fervenza.1'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 mg/kg once daily for 2 to 4 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1620812','lexi-content-ref-KDIGO.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1620812','lexi-content-ref-KDIGO.2012'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4f575b1-9ab5-4ea5-b16e-1724f4fcbc62">Multiple myeloma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Multiple myeloma (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">CyBorD regimen: <b>Oral:</b> 300 mg/m<sup>2</sup> on days 1, 8, 15, and 22 every 4 weeks (in combination with bortezomib and dexamethasone) for 4 cycles; may continue beyond 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22107129']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22107129'])">Ref</a></span>) <b>or </b>500 mg/m<sup>2</sup> on days 1, 8, and 15 every 3 weeks (in combination with bortezomib and dexamethasone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22422823']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22422823'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">VDT-PACE regimen: <b>IV:</b> 400 mg/m<sup>2</sup>/day administered as a continuous infusion on days 1 to 4 of each cycle; repeat every 4 to 6 weeks (in combination with bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, and etoposide) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12860952','lexi-content-ref-18302711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12860952','lexi-content-ref-18302711'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6d4c856e-dedc-4b57-9bc3-4eb783e31618">Non-Hodgkin lymphomas</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-Hodgkin lymphomas (off-label dosing):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Burkitt lymphoma</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">CALGB 10002 regimen (cycles 1, 3, 5, and 7): <b>IV:</b> 200 mg/m<sup>2</sup>/day on days 1 to 5 every 3 weeks (in combination with vincristine, prednisone, ifosfamide, dexamethasone, methotrexate, leucovorin, cytarabine, etoposide, rituximab, doxorubicin, intrathecal therapy, and filgrastim); refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24428673']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24428673'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CODOX-M/IVAC: Cycles 1 and 3 (CODOX-M): <b>IV: </b>800 mg/m<sup>2</sup> on day 1, followed by 200 mg/m<sup>2</sup>/day on days 2 to 5 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8622041']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8622041'])">Ref</a></span>) <b>or</b> 800 mg/m<sup>2</sup>/day on days 1 and 2 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15160953']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15160953'])">Ref</a></span>), in combination with vincristine, doxorubicin, and methotrexate; CODOX-M alternates with IVAC (etoposide, ifosfamide, mesna, and cytarabine) for a total of 4 cycles.</p>
<p style="text-indent:-2em;margin-left:6em;">R-Hyper-CVAD: <b>IV: </b>300 mg/m<sup>2</sup> every 12 hours on days 1 to 3 (total of 6 doses) of courses 1, 3, 5, and 7 (in combination with rituximab, mesna, vincristine, doxorubicin, and dexamethasone) and alternates with even courses 2, 4, 6, and 8 (rituximab, methotrexate and cytarabine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16502413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16502413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Diffuse large B-cell lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CHOP/R-CHOP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 every 3 weeks (in combination with rituximab, doxorubicin, vincristine, and prednisone) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11807147']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11807147'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Dose-adjusted EPOCH/EPOCH-R regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 5 every 3 weeks (in combination with rituximab, etoposide, prednisone, vincristine, and doxorubicin) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17233819']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17233819'])">Ref</a></span>). Refer to protocol for dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:6em;">Pola-R-CHP regimen (previously untreated diffuse large B-cell lymphoma): <b>IV:</b> 750 mg/m<sup>2</sup> on day 1 every 21 days (in combination with polatuzumab vedotin, rituximab, doxorubicin, and prednisone) for 6 cycles; following the completion of 6 cycles of Pola-R-CHP, rituximab monotherapy was continued for 2 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34904799']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34904799'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">R-CEOP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle for 3 to 6 cycles (in combination with rituximab, vincristine, etoposide, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moccia.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moccia.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Follicular lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CVP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with vincristine and prednisone [± rituximab or obinutuzumab]) for 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15494430','lexi-content-ref-28976863']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15494430','lexi-content-ref-28976863'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">R-CHOP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle for 6 to 8 cycles (in combination with rituximab, vincristine, doxorubicin, and prednisone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16123223']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16123223'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Peripheral T-cell lymphoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">BV-CHP (or A-CHP) regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with brentuximab vedotin, doxorubicin, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30522922']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30522922'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CHOEP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with vincristine, doxorubicin, etoposide, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14982884','lexi-content-ref-20660290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14982884','lexi-content-ref-20660290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">CHOP regimen: <b>IV: </b>750 mg/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with vincristine, doxorubicin, and prednisone) for 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20660290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20660290'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Primary mediastinal B-cell lymphoma:</i> DA-EPOCH-R regimen: <b>IV:</b> 750 mg/m<sup>2</sup> as a 2-hour infusion on day 5, dose-adjusted for subsequent cycles based on neutrophil and platelet counts during nadir (in combination with etoposide, prednisone, vincristine, doxorubicin, rituximab, and filgrastim); repeat cycle every 3 weeks for a total of 6 to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23574119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23574119'])">Ref</a></span>). Refer to protocol for dosage adjustments.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Other non-</i>
<i>Hodgkin lymphoma regimens:</i></p>
<p style="text-indent:-2em;margin-left:6em;">CEPP(B) regimen: <b>IV:</b> Initial: 600 mg/m<sup>2</sup> on days 1 and 8; may increase dose with subsequent cycles (refer to protocol for details) every 28 days (in combination with etoposide, procarbazine, prednisone, ± bleomycin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2207307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2207307'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">PEP-C regimen: <b>Oral:</b> 50 mg (flat dose) once daily after lunch (length of induction cycle depends on blood counts; frequency may vary based on tolerance in maintenance cycle [refer to protocol for details]; in combination with prednisone, etoposide, and procarbazine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18338745']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18338745'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="13f17875-1d07-41d4-8339-786ab9b68d36">Osteosarcoma, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Osteosarcoma, relapsed/refractory (off-label use): IV:</b> 500 mg/m<sup>2</sup>/day on days 1 to 5 every 21 to 28 days (in combination with mesna, etoposide, and growth factor support) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11972091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11972091'])">Ref</a></span>) or 4,000 mg/m<sup>2</sup> as a 3-hour infusion on day 1 (in combination with mesna and etoposide) every 21 to 28 days for 2 cycles; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19452540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19452540'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a8f2dab-e7cd-4a3d-9784-cb1523635595">Ovarian germ cell tumors, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ovarian germ cell tumors, malignant (off-label use):</b>
<b>IV:</b> 150 mg/m<sup>2</sup> on days 1 to 5 every 28 days (in combination with dactinomycin and vincristine) for at least 10 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2988740']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2988740'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60a3049d-932f-4cb6-8b42-d79eefa7ea93">Pheochromocytoma, malignant</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pheochromocytoma, malignant (off-label use):</b>
<b>IV:</b> 750 mg/m<sup>2</sup> on day 1 every 3 or 4 weeks (in combination with dacarbazine and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18780317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18780317'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce826313-7a35-4452-ade2-2b98db2927f6">Pneumonitis, immune checkpoint inhibitor-induced, grade 3 or 4, steroid-refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-4em;margin-left:4em;">
<b>Pneumonitis, immune checkpoint inhibitor-induced, grade 3 or 4, steroid-refractory (off-label use): Oral:</b> 1 to 2 mg/kg once daily (as an add on to corticosteroids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d2977a43-edb5-49b3-9eca-72cb75c70c75">Polyarteritis nodosa, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Polyarteritis nodosa, moderate to severe (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Some experts prefer the regimen identified as “preferred” below based on clinical experience and data in patients with antineutrophil cytoplasmic antibody-associated vasculitis; this regimen has not been studied in polyarteritis nodosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Merkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Merkel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (preferred regimen): </b>15 mg/kg (maximum: 1,200 mg) once every 2 weeks for 3 doses, followed by 15 mg/kg (maximum: 1,200 mg) once every 3 weeks for 3 to 6 months (in combination with glucocorticoids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19451574','lexi-content-ref-22128076','lexi-content-ref-Merkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19451574','lexi-content-ref-22128076','lexi-content-ref-Merkel.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV: </b>600 mg/m<sup>2</sup> once every 2 weeks for 3 doses, then once every 4 weeks thereafter (in combination with glucocorticoids) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9448590','lexi-content-ref-7488285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9448590','lexi-content-ref-7488285'])">Ref</a></span>). Maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>2 mg/kg once daily in combination with glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9448590','lexi-content-ref-1676753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9448590','lexi-content-ref-1676753'])">Ref</a></span>). Maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy</b>
<b>: </b>Continue therapy for ≥4 months and until disease remission is achieved (maximum duration: 6 months); some experts limit duration to 4 months if remission is achieved by then. Once remission is achieved, transition to an alternative immunosuppressive agent to maintain remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18413444','lexi-content-ref-1676753','lexi-content-ref-7488285','lexi-content-ref-Merkel.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18413444','lexi-content-ref-1676753','lexi-content-ref-7488285','lexi-content-ref-Merkel.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="742c866d-624d-41cf-a1cb-742554aedc03">Primary CNS lymphoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary CNS lymphoma (off-label use):</b> TBC conditioning regimen: <b>IV: </b>60 mg/kg/day for 2 days beginning 3 days prior to transplant (in combination with thiotepa and busulfan), followed by autologous cell transplant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28369839','lexi-content-ref-11157026','lexi-content-ref-18413641']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28369839','lexi-content-ref-11157026','lexi-content-ref-18413641'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4108c25e-0a7a-4e46-bbb2-755705ef68b8">Pure red cell aplasia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pure red cell aplasia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with acquired pure red cell aplasia (PRCA) that is not self-limiting and is refractory to other preferred agents, <b>or</b> as initial therapy in patients with PRCA due to anti-erythropoiesis-stimulating agent antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.1','lexi-content-ref-Means.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.1','lexi-content-ref-Means.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>50 to 100 mg once daily (in combination with glucocorticoids); initial improvement may be observed after as early as 8 weeks, and complete response after a median of 3 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16099877','lexi-content-ref-15172775','lexi-content-ref-9163606']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16099877','lexi-content-ref-15172775','lexi-content-ref-9163606'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Acquired PRCA: </i>Continue therapy for up to 6 months, then transition to an alternative immunosuppressive agent to maintain remission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18510682']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18510682'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>PRCA due to anti-erythropoiesis-stimulating agent antibodies:</i> Continue treatment until antibody levels become undetectable; switch to alternative therapy if there is no response within 3 to 4 months of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berns.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berns.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f5504217-4a06-41a9-8929-da042d28bae3">Rhabdomyosarcoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhabdomyosarcoma (off-label use):</b> Adults &lt;50 years: <i>VAC regimen:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Low risk: <b>IV: </b>1,200 mg/m<sup>2</sup> every 21 days (in combination with mesna, vincristine, and dactinomycin) for 4 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25267746']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25267746'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Intermediate risk: <b>IV: </b>2,200 mg/m<sup>2</sup> every 21 days (in combination with mesna, vincristine, and dactinomycin) for 14 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19770373']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19770373'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c44ba3ae-9b89-4ba0-8466-3b197de98c07">Small cell lung cancer, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Small cell lung cancer, refractory (off-label use):</b>
<b>IV:</b> 1,000 mg/m<sup>2</sup> (maximum: 2,000 mg) on day 1 every 3 weeks (in combination with doxorubicin and vincristine) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10080612']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10080612'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a4d4718b-e0ee-4bda-871f-113cd0b52efe">Systemic light chain amyloidosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic light chain amyloidosis (off-label use):</b></p>
<p style="text-indent:0em;margin-left:2em;">
<i>CRd regimens: </i>
<b>IV or Oral: </b>300 mg/m<sup>2</sup>
<b>orally</b> on days 1, 8, and 15 of a 28-day cycle (in combination with lenalidomide and dexamethasone); cyclophosphamide was administered for a maximum of 12 cycles; refer to protocol for further information (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22504925']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22504925'])">Ref</a></span>) <b>or</b> 300 mg/m<sup>2</sup>
<b>IV</b> on days 1 and 8 every 28 days (in combination with lenalidomide and dexamethasone) for 6 cycles, followed by 300 mg/m<sup>2</sup>
<b>IV</b> on day 1 only every 28 days (in combination with lenalidomide and dexamethasone) for 6 additional cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25974382']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25974382'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>CyBorD regimen:</i>
<b>Oral:</b> 300 mg/m<sup>2</sup> once weekly (in combination with bortezomib and dexamethasone) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22331188','lexi-content-ref-25987656']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22331188','lexi-content-ref-25987656'])">Ref</a></span>) <b>or</b> 350 mg/m<sup>2</sup> on days 1, 8, and 15 (in combination with bortezomib and dexamethasone) for up to 8 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22331187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22331187'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="77a414e3-8238-44a4-9760-d8540619bdcc">Systemic sclerosis–related interstitial lung disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Systemic sclerosis–related interstitial lung disease (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use in patients with features suggesting high risk for progression (eg, declining pulmonary function) or with symptomatic interstitial lung disease. Generally administered in combination with low-dose glucocorticoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Varga.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Varga.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV (preferred route): </b>600 mg/m<sup>2</sup> once every 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17133610']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17133610'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 1,200 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 1 mg/kg/day (rounded to the nearest 25 mg); may increase daily dose based on response and tolerability by 25 mg once monthly up to 2 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16790698']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16790698'])">Ref</a></span>); maximum dose has not been established; some experts do not exceed 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-McCune.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-McCune.1'])">Ref</a></span>), <b>or</b> 50 to 100 mg daily initially (50 mg daily for patients weighing &lt;81 kg and 100 mg daily for patients weighing ≥81 kg), followed by increases in 25 to 50 mg increments each month up to 2 mg/kg/day (maximum: 200 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27469583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27469583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Duration of therapy: </b>Limit duration of IV therapy to 6 months or oral therapy to 12 months, then transition to an alternative immunosuppressive agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17133610','lexi-content-ref-16790698','lexi-content-ref-27469583','lexi-content-ref-Varga.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17133610','lexi-content-ref-16790698','lexi-content-ref-27469583','lexi-content-ref-Varga.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7c5acfef-6596-497f-90bd-63216cb2807e">T-cell prolymphocytic leukemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>T-cell prolymphocytic leukemia (off-label use): </b>
<i>FMC-A regimen: </i>
<b>IV:</b> 200 mg/m<sup>2</sup> on days 1, 2, and 3 every 28 days (in combination with fludarabine and mitoxantrone [FMC]) for a total of 2 to 4 cycles; if response demonstrated after initial 2 FMC cycles, then an additional 2 cycles of FMC were administered, followed by alemtuzumab consolidation; if stable disease or progression observed after initial 2 FMC cycles, then proceeded directly to alemtuzumab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23512246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23512246'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54ae694a-2fc6-475a-b2a0-8dd149c25978">Thymomas, advanced or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Thymomas, advanced or metastatic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>ADOC regimen:</i>
<b>IV: </b>700 mg/m<sup>2</sup> on day 4 every 3 weeks (in combination with doxorubicin, cisplatin, and vincristine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2049749']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2049749'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>CAP regimen:</i>
<b>IV: </b>500 mg/m<sup>2</sup> on day 1 every 3 weeks for up to 8 cycles (in combination with cisplatin and doxorubicin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8201378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8201378'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ebda9a81-6b8d-4064-acf9-5c892f36549f">Waldenström macroglobulinemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Waldenström macroglobulinemia (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>DRC regimen:</i>
<b>Oral:</b> 100 mg/m<sup>2</sup> twice daily on days 1 to 5 every 21 days (in combination with dexamethasone and rituximab) for 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17577016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17577016'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>FCR regimen:</i>
<b>IV:</b> 250 mg/m<sup>2</sup> once daily on days 2 to 4 every 28 days (in combination with fludarabine and rituximab) for up to 6 cycles (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21732338']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21732338'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="08d69855-2c21-43df-8d0d-4d45d6e80e3e">Warm autoimmune hemolytic anemia, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Warm autoimmune hemolytic anemia, relapsed/refractory </b>
<b>(alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Low-dose therapy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 1 to 2 mg/kg once daily (maximum dose is not established) <b>or</b> 50 to 150 mg once daily, with or without concomitant glucocorticoids; response typically achieved within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360039','lexi-content-ref-26696797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360039','lexi-content-ref-26696797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>High-dose therapy: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Generally reserved for patients with refractory disease or severe anemia due to greater potential for toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26696797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26696797'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>1,000 mg once every 4 weeks for 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28360039','lexi-content-ref-25435734']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28360039','lexi-content-ref-25435734'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991622"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Specific recommendations for kidney dose adjustment have not been established. A dose-effect relationship is difficult to determine due to interpatient variability in pharmacokinetics and pharmacodynamics, and the complex metabolism and precise mechanism of action are not completely understood (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11918757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11918757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">The following general and indication-specific dosage adjustments have been recommended. Use with caution, especially with more severe impairment; consider indication, goals of therapy, and risks versus benefits when selecting a dose, and monitor for signs and symptoms of toxicity; also refer to institution-specific protocols (when available):</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>General dosage adjustment recommendations: </i>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:6em;">CrCl ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl 10 to 29 mL/minute: Administer 75% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>) or 100% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1','lexi-content-ref-7859226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1','lexi-content-ref-7859226'])">Ref</a></span>) of normal dose.</p>
<p style="text-indent:-2em;margin-left:6em;">CrCl &lt;10 mL/minute: Administer 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>), 75% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>), or 100% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7859226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7859226'])">Ref</a></span>) of normal dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Moderately dialyzable (20% to 50% removal based on limited data with low-flux dialyzers (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11918757','lexi-content-ref-Nemecek.1','lexi-content-ref-7471607']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11918757','lexi-content-ref-Nemecek.1','lexi-content-ref-7471607'])">Ref</a></span>)).</p>
<p style="text-indent:-2em;margin-left:6em;">Administer 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30942181']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30942181'])">Ref</a></span>) or 75% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20118214','lexi-content-ref-29209521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20118214','lexi-content-ref-29209521'])">Ref</a></span>) of the normal dose. On dialysis days, administer after hemodialysis, allowing at least 12 hours before the next hemodialysis session (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11918757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11918757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Administer 75% of the normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>). If possible, allow at least 12 hours before next peritoneal dialysis exchange (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>CRRT:</b> Administer 100% of the normal dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>
<i>Indication-specific dosage adjustments:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Granulomatosis with polyangiitis or microscopic polyangiitis:</b></p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Cyclophosphamide Oral Initial Dosage Adjustment for Granulomatosis With Polyangiitis or Microscopic Polyangiitis<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">CrCl</p></th>
<th align="center">
<p style="text-indent:0em;">Cyclophosphamide oral dose (mg/kg/day)<sup>b</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>Regan 2001; Merkel 2021b.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>Maximum dose: 200 mg/dose (de Groot 2009).</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">≥100 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">2 mg/kg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">50 to &lt;100 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1.5 mg/kg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">25 to &lt;50 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1.2 mg/kg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to &lt;25 mL/minute</p></td>
<td align="center">
<p style="text-indent:0em;">1 mg/kg/day</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;15 mL/minute or on dialysis</p></td>
<td align="center">
<p style="text-indent:0em;">0.8 mg/kg/day</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Cyclophosphamide IV Dosage Adjustment for Granulomatosis With Polyangiitis or Microscopic Polyangiitis<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center">
<p style="text-indent:0em;">Age</p></th>
<th align="center">
<p style="text-indent:0em;">CrCl &gt;30 mL/minute<sup>b,d,e</sup></p></th>
<th align="center">
<p style="text-indent:0em;">CrCl &lt;30 mL/minute<sup>b,c,d,e</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>de Groot 2009.</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>The original protocol reduced doses when SCr was above 3.4 mg/dL (300 mcmol/L), but in clinical practice this has often been translated as a CrCl &lt;30 mL/minute (expert opinion).</p>
<p style="text-indent:0em;text-align:left;">
<sup>c </sup>Some experts use a reduced dose of 7.5 mg/kg in all patients with CrCl &lt;30 mL/minute regardless of age (Merkel 2021b).</p>
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Maximum dose: 1,200 mg/dose (de Groot 2009).</p>
<p style="text-indent:0em;text-align:left;">
<sup>e </sup>Doses are administered every 2 weeks for 3 doses, followed by maintenance pulses every 3 weeks for 3 months after remission achieved.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">&lt;60 years</p></td>
<td align="center">
<p style="text-indent:0em;">15 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">12.5 mg/kg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">60 to 70 years</p></td>
<td align="center">
<p style="text-indent:0em;">12.5 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg/kg</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;70 years</p></td>
<td align="center">
<p style="text-indent:0em;">10 mg/kg</p></td>
<td align="center">
<p style="text-indent:0em;">7.5 mg/kg</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hematopoietic stem cell transplantation:</b> There are no specific dosage adjustments recommended; a reduced dose may be considered in moderate to severe impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24565993']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24565993'])">Ref</a></span>). Refer to "General Dosage Adjustment Recommendations" for patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Lupus nephritis:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>Shorter, low-dose regimen (500 mg IV once every 2 weeks for 6 doses): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25403681','lexi-content-ref-12209517']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25403681','lexi-content-ref-12209517'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV: </b>Longer, high-dose regimen (500 to 1,000 mg/m<sup>2 </sup>IV pulses):</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &gt;30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">CrCl &lt;30 mL/minute: Reduce initial dose to 500 mg/m<sup>2</sup> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3511372','lexi-content-ref-8815753']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3511372','lexi-content-ref-8815753'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral regimen:</b> Refer to “General Dosage Adjustment Recommendations” for patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Multiple myeloma: Oral:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26976420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26976420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Hemodialysis: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26976420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26976420'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988893"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The conversion between cyclophosphamide to the active metabolite may be reduced in patients with severe hepatic impairment, potentially reducing efficacy. Some dosage forms may contain ethanol; consider alcohol content of the product when administering to patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>The following adjustments have been recommended:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Floyd 2006:</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin 3.1 to 5 mg/dL or transaminases &gt;3 times ULN: Administer 75% of dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Serum bilirubin &gt;5 mg/dL: Avoid use.</p>
<p style="text-indent:-2em;margin-left:4em;">Krens 2019:</p>
<p style="text-indent:-2em;margin-left:6em;">Mild or moderate impairment: Dosage adjustment is not likely needed.</p>
<p style="text-indent:-2em;margin-left:6em;">Severe impairment: Use is not recommended due to risk of reduced efficacy.</p></div>
<div class="block arsc drugH1Div" id="F57087380"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone marrow suppression and infection</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Leukopenia</b>, <b>neutropenia</b>, <b>thrombocytopenia</b>, and <b>anemia</b> commonly occur. Bone marrow failure has been reported. Bone marrow failure and severe immunosuppression may lead to serious (and fatal) infections, including sepsis and septic shock, or reactive latent infections. Serious infections have been reported in patients receiving high-dose concurrent corticosteroids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33275674','lexi-content-ref-8814058']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33275674','lexi-content-ref-8814058'])">Ref</a></span>). No difference has been found between oral and intravenous cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33275674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33275674'])">Ref</a></span>). Recovery of platelet and neutrophil nadirs is expected after ~20 days.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2025981']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2025981'])">Ref</a></span>); related to pharmacologic action. Alkylating agent that induces DNA damage in all rapidly dividing cells, including those of the bone marrow (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33275674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33275674'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; platelet and neutrophil nadirs are usually at weeks 1 and 2 of treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent corticosteroid use (≥20 mg/day of prednisone equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29276769','lexi-content-ref-18679133','lexi-content-ref-28134084']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29276769','lexi-content-ref-18679133','lexi-content-ref-28134084'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent/multidrug chemotherapy and/or radiation therapy</p>
<p style="text-indent:-2em;margin-left:6em;">• Heavy pretreatment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiotoxicities reported include arrhythmias (<b>supraventricular cardiac arrhythmia</b> and <b>ventricular arrhythmia</b> [some with <b>prolonged QT interval on ECG</b>]), <b>heart failure</b>, heart block, hemopericardium (secondary to hemorrhagic <b>myocarditis</b> and myocardial necrosis), myocarditis (including fatal hemorrhagic), <b>pericarditis</b>, <b>pericardial effusion </b>including <b>cardiac tamponade</b>, and tachyarrhythmias.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; not clearly established. Metabolites, specifically acrolein and/or phosphoramide mustard, are believed to cause oxidative stress to the myocardium and direct endothelial capillary damage. This leads to extravasation of erythrocytes, proteins, and toxic metabolites that cause direct damage to the myocardium, manifesting as arrhythmias and/or heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30552952']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30552952'])">Ref</a></span>). Capillary microthrombosis and fibrin deposition occur with cyclophosphamide-induced cardiac injury (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425570'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; usually within the first 48 hours but may occur up to 10 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26425570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26425570'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses commonly used in hematopoietic stem cell transplantation. Acute heart failure is reported in 7% to 33% of patients receiving a total dose &gt;150 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2045862','lexi-content-ref-7235784','lexi-content-ref-27079957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2045862','lexi-content-ref-7235784','lexi-content-ref-27079957'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting arrhythmias, cardiac disease, diabetes, hypertension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34592759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34592759'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (&gt;55 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34592759']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34592759'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior radiation therapy to the chest</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior or concurrent cardiotoxic medications</p>
<p style="text-indent:-2em;margin-left:6em;">• Heavy pretreatment</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hemorrhagic cystitis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cyclophosphamide is associated with the development of <b>hemorrhagic cystitis</b>, which may lead to <b>pyelitis</b>, <b>ureteral disease </b>(ureteritis), and <b>hematuria</b>. Hemorrhagic cystitis may rarely be severe or fatal. <b>Bladder fibrosis</b>, necrosis or contracture may also occur, either with or without cystitis. Occurrence of hemorrhagic cystitis increases risk of bladder cancer. While hematuria generally resolves within a few days after treatment is withheld, it may persist in some cases.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and duration-related; hemorrhagic cystitis is due to excretion of cyclophosphamide metabolite, acrolein, in the urine. Acrolein irritates the lining of the bladder, specifically the transitional cells, causing damage and sloughing of those cells leading to hemorrhagic cystitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34943985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34943985'])">Ref</a></span>). Chloroacetaldehyde may also be implicated in bladder and kidney toxicity through oxidative effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31598736']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31598736'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; within hours or days of treatment with intravenous cyclophosphamide (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880225'])">Ref</a></span>), but may occur up to a median of 2 weeks later (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34108676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34108676'])">Ref</a></span>). With oral therapy for Wegener granulomatosis, median time to development was 37 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8602705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8602705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses associated such as with bone marrow transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cumulative dose when used in rheumatic diseases (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26178288']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26178288'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• In bone marrow transplant, male patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26168069']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26168069'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Active urinary tract infections, especially BK viruria, or obstructions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23880225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23880225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration (due to lower frequency of voiding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34108676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34108676'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34108676']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34108676'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hepatotoxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic sinusoidal obstruction syndrome</b> (SOS), formerly called veno-occlusive liver disease, has been reported in patients receiving chemotherapy regimens containing cyclophosphamide. Signs and symptoms of hepatic SOS include bilirubin &gt;1.4 mg/dL, unexplained weight gain, <b>ascites</b>, <b>hepatomegaly</b>, and unexplained right upper quadrant pain (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15143082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15143082'])">Ref</a></span>). Patients may also experience <b>cholestatic hepatitis</b> or <b>cytolytic</b>
<b>hepatitis</b>, including <b>hepatic failure</b> with associated liver function test abnormalities and sequelae.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Direct toxicity of cyclophosphamide and its metabolites (phosphoramide mustard and acrolein) to hepatic sinusoids (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12406916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12406916'])">Ref</a></span>). These metabolites induce oxidative stress by producing free radicals that inhibit the activity of antioxidant enzymes such as superoxide dismutase, glutathione, and catalase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30271446']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30271446'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; typically, within 2 to 8 weeks of initiation. Onset has also been reported 12 hours up to approximately 10 months after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21738257','lexi-content-ref-3060893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21738257','lexi-content-ref-3060893'])">Ref</a></span>). In the case of transplantation, onset of SOS has been reported within 20 days of myeloablation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12406916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12406916'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Cytoreductive conditional transplantation regimens in combination with total body irradiation, busulfan or other hepatotoxic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12406916']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12406916'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent azathioprine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3060893']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3060893'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent dactinomycin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15143082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15143082'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term lower doses for immunosuppressive indications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21738257','lexi-content-ref-24023976']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21738257','lexi-content-ref-24023976'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting hepatic dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6468474']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6468474'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior radiation to the abdominal area (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25071139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25071139'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Children &lt;3 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15143082']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15143082'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with CYP2B6*7 variant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31686598']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31686598'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pulmonary toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Pulmonary toxicity, including<b> pneumonitis</b>, <b>pulmonary fibrosis</b>, <b>pulmonary veno-occlusive disease</b>, and <b>acute respiratory distress syndrome</b>, have been reported. Pulmonary toxicity may be difficult to identify due to confounding pulmonary conditions occurring in the same population, including infections and pulmonary malignancies. This toxicity often presents as dyspnea, fever, cough, parenchymal infiltrates, abnormal pulmonary function tests and pleural thickening. Early onset pulmonary toxicity may be reversible, but late onset is associated with pleural thickening and may persist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8970380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8970380'])">Ref</a></span>). Late onset pneumonitis develops rarely in patients receiving prolonged treatment over several months to years with lower doses of cyclophosphamide and may be associated with increased mortality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12583625','lexi-content-ref-8970380','lexi-content-ref-3604756']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12583625','lexi-content-ref-8970380','lexi-content-ref-3604756'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Exact mechanism unknown; metabolism of cyclophosphamide in lung to alkylating metabolites and acrolein, a reactive aldehyde, is in part responsible for pulmonary toxicity. Acrolein may cause direct injury to the pulmonary epithelium, leading to alveolitis and fibrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9048121','lexi-content-ref-11485142']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9048121','lexi-content-ref-11485142'])">Ref</a></span>). Alterations in pulmonary mixed-function oxidase activity, glutathione content, along with cyclophosphamide- and acrolein-induced alterations in the physical state of membrane lipid bilayer may be the major cause of inactivation of membrane-bound enzymes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2195554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2195554'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; onset can be early (within 1 to 6 months of initiation) or late (several months to years after initiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8970380']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8970380'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Oxygen therapy (hyperoxic conditions) may potentiate the effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-2195554']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-2195554'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of pulmonary toxic medications, including bleomycin, busulfan, and carmustine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10992015','lexi-content-ref-23603381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10992015','lexi-content-ref-23603381'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior or concurrent thoracic radiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11429481','lexi-content-ref-16199317']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11429481','lexi-content-ref-16199317'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent therapies such as amiodarone and G-CSF or GM-CSF</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting lung disease</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Second primary malignancy</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary primary malignant neoplasm</b> (<b>acute leukemia</b>, <b>bladder carcinoma</b>, <b>malignant lymphoma</b>, <b>malignant neoplasm of thyroid</b>, <b>myelodysplastic syndrome</b>, <b>sarcoma</b>, and other solid tumors) have been reported with both single-agent cyclophosphamide and with combination chemotherapy regimens.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; as an alkylating agent, cyclophosphamide is directly genotoxic. DNA-induced damage causes double-strand breaks, leading to genomic instability due to loss of DNA repair (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16294218','lexi-content-ref-9449873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16294218','lexi-content-ref-9449873'])">Ref</a></span>). Inherited genetic polymorphisms may affect the risk post-alkylator exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16707424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16707424'])">Ref</a></span>). Bladder inflammation, secondary to acrolein exposure, is also associated with increased risk of bladder cancer after therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34134927']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34134927'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; several years to decades after treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28530852']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28530852'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher cumulative doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10817555','lexi-content-ref-23101661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10817555','lexi-content-ref-23101661'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses associated with stem cell transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15753460','lexi-content-ref-20926773']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15753460','lexi-content-ref-20926773'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other carcinogenic chemotherapy agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19204201','lexi-content-ref-11830608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19204201','lexi-content-ref-11830608'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients previously experiencing hemorrhagic cystitis (bladder cancer)</p>
<p style="text-indent:-2em;margin-left:6em;">• Tobacco smoking (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11830608']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11830608'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F155418"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (Yeh 2021), atrial fibrillation (Yeh 2021), atrial flutter (Yeh 2021), bradycardia, cardiac tamponade (Yeh 2021), cardiogenic shock, cardiomyopathy, chest pain, edema, flushing, heart failure (Yeh 2021), hemorrhagic myocarditis, hypertension, hypotension, myocarditis, palpitations, pericardial effusion (Yeh 2021), pericarditis (Yeh 2021), peripheral ischemia, prolonged QT interval on ECG, pulmonary embolism, supraventricular cardiac arrhythmia (Yeh 2021), tachycardia, vasculitis, venous thrombosis, ventricular arrhythmia (Yeh 2021), ventricular fibrillation, ventricular tachyarrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, changes in nails, dermatitis, erythema multiforme, erythema of skin, hyperhidrosis, palmar-plantar erythrodysesthesia, pruritus, skin abnormalities related to radiation recall, skin blister, skin rash, skin toxicity, Stevens-Johnson syndrome (Assier-Bonnet 1996), toxic epidermal necrolysis (Sasak 2016), urticaria (Thong 2002)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, decreased serum glucose, fluid retention, hot flash, hyponatremia (Chen 2020; Esposito 2017; Gilbar 2012), increased lactate dehydrogenase, increased serum glucose, malignant neoplasm of thyroid, nephrogenic diabetes insipidus, water intoxication</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Acute pancreatitis, ageusia, cholestasis, colitis, constipation, dysgeusia, enteritis, gastrointestinal hemorrhage, hemorrhagic colitis, nausea, neutropenic typhlitis, oral mucosa ulcer, parotitis, stomatitis, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Azoospermia, bladder carcinoma (Brown 2005), bladder disease (necrosis, contracture, or atypical epithelial cells), cystitis (ulcerative), defective oogenesis, defective spermatogenesis, hematuria (Wang 2015), hemorrhagic cystitis (Wang 2015), infertility, infrequent uterine bleeding, oligospermia, ovarian failure, ovarian fibrosis, premature labor, pyelitis, testicular atrophy, toxic nephrosis, ureteral disease (ureteritis)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (Malpica 2020), bone marrow depression (including bone marrow failure) (Malpica 2020), C-reactive protein increased, disseminated intravascular coagulation, febrile neutropenia, hemolytic-uremic syndrome, leukopenia (Malpica 2020), myelodysplastic syndrome (Brown 2005), neutropenia (Malpica 2020), pulmonary hemorrhage, secondary primary malignant neoplasm (including acute leukemia, malignant lymphoma, malignant neoplasm of urinary tract [pelvic, renal, and ureteric], myelatelia, sarcoma) (Brown 2005), thrombocytopenia (Malpica 2020), thrombotic microangiopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Ascites (Arndt 2004), cholestatic hepatitis, hepatic encephalopathy, hepatic failure (Arndt 2004), hepatic sinusoidal obstruction syndrome (Arndt 2004), hepatitis (including hepatic cytolysis), hepatomegaly (Arndt 2004), increased liver enzymes (Arndt 2004), increased serum bilirubin (Arndt 2004), jaundice (Arndt 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis (Garas 1995; Jones 1989), facial swelling</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immunosuppression (Malpica 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Cytomegalovirus disease (Goldsmith 2021), infection (including reactivation of latent infection)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion-site reaction (including erythema, inflammation, necrosis, pain, phlebitis, swelling, and thrombosis), injection-site reaction (including erythema at injection site, inflammation at injection site, injection-site phlebitis, pain at injection site, swelling at injection site, tissue necrosis at injection site, venous thrombosis at injection site)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered sense of smell, asthenia, chills, confusion, dizziness, dysesthesia, encephalopathy, fatigue, headache, hypoesthesia, malaise, neuralgia, neurotoxicity, pain, paresthesia, peripheral neuropathy, polyneuropathy, reversible posterior leukoencephalopathy syndrome, seizure, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle spasm, myalgia, myelopathy, rhabdomyolysis, systemic sclerosis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis, lacrimation, visual impairment</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Auditory impairment, deafness, tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Hemorrhagic ureteritis, renal cell carcinoma, renal failure syndrome, renal insufficiency, renal tubular disease</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome (Malik 1996), bronchiolitis obliterans, bronchospasm, cough, dyspnea, flu-like symptoms, hypersensitivity pneumonitis, hypoxia, interstitial pulmonary disease, nasal congestion, nasal discomfort, oropharyngeal pain, pleural effusion, pneumonia, pneumonitis (can be late onset [&gt;6 months]) (Malik 1996), pulmonary edema, pulmonary fibrosis (Malik 1996), pulmonary hypertension, pulmonary veno-occlusive disease, respiratory distress (Malik 1996), respiratory failure (Malik 1996), rhinorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever, multi-organ failure</p></div>
<div class="block coi drugH1Div" id="F155434"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of severe hypersensitivity to cyclophosphamide, its metabolites, or any component of the formulation; urinary outflow obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Severe myelosuppression, severe renal or hepatic impairment, active infection (especially varicella zoster), severe immunosuppression.</p></div>
<div class="block war drugH1Div" id="F155415"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Possible cross-sensitivity with other alkylating agents may occur.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in hepatic impairment; see "Dosing: Hepatic Impairment" for additional information.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; see "Dosing: Altered Kidney Function" for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cyclophosphamide injection: Some cyclophosphamide injection dosage forms may contain alcohol. The alcohol content (in some dosage forms) may affect the CNS and impair the ability to drive or operate machinery; review available dosage forms for ethanol content in order to select the appropriate product, particularly for patients who should avoid or minimize alcohol intake, including patients with hepatic impairment.</p></div>
<div class="block foc drugH1Div" id="F155426"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg/2.5 mL (2.5 mL); 500 mg/mL (1 mL, 2 mL, 4 mL); 1 g/5 mL (5 mL); 2 g/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg (1 ea); 1 g (1 ea); 2 g (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F155411"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F155437"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (cycloPHOSphamide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.42 - $9.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $4.80 - $17.75</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (cycloPHOSphamide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g/5 mL (per mL): $92.53 - $175.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g/10 mL (per mL): $100.94 - $175.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/2.5 mL (per mL): $74.50 - $175.80</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/mL (per mL): $438.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (cycloPHOSphamide Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 g (per each): $301.68 - $879.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 g (per each): $540.68 - $1,758.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $137.50 - $439.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (cycloPHOSphamide Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $5.05</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866473"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procytox: 200 mg (1 ea); 500 mg (1 ea); 1 g (50 mL); 2 g (100 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Procytox: 25 mg, 50 mg</p></div>
<div class="block exp drugH1Div" id="F155432"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;">Liquid solutions for oral administration may be prepared by dissolving cyclophosphamide injection in Aromatic Elixir, N.F. Store refrigerated (in glass container) for up to 14 days.</p>
<div class="reference">Cyclophosphamide Prescribing Information, Baxter Healthcare Corporation, Deerfield, Il, May, 2013.<span class="pubmed-id">20103616</span></div>
<p style="text-indent:0em;margin-top:2em;">A 10 mg/mL oral suspension may be prepared by reconstituting one 2 g vial for injection with 100 mL of NaCl 0.9%, providing an initial concentration of 20 mg/mL. Mix this solution in a 1:1 ratio with either Simple Syrup, NF or Ora-Plus to obtain a final concentration of 10 mg/mL. Label “shake well” and “refrigerate”. Stable for 56 days refrigerated.</p>
<div class="reference">Kennedy R, Groepper D, Tagen M, et al, "Stability of Cyclophosphamide in Extemporaneous Oral Suspensions," <i>Ann Pharmacother</i>, 2010, 44(2):295-301.<span class="pubmed-id">20103616</span></div>
</div>
<div class="block admp drugH1Div" id="F52612467"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Antiemetics may be recommended to prevent nausea and vomiting; doses ≥1,200 mg/m<sup>2</sup> IV are associated with a high emetic potential and doses of 1,000 mg/m<sup>2</sup> IV are associated with a moderate emetic risk (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21465637','lexi-content-ref-30729654']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21465637','lexi-content-ref-30729654'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Capsules and tablets should be swallowed whole. Tablets are not scored and should not be cut, crushed, or chewed. Capsules should not be opened, crushed, or chewed. Wear gloves when handling capsules/tablets and container; avoid exposure to broken capsules. If exposure to capsule contents or crushed/cut tablets, wash hands immediately and thoroughly. Morning administration may be preferred to ensure adequate hydration throughout the day; do not administer tablets/capsules at bedtime.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IV push: May administer reconstituted solution without further dilution (20 mg/mL); rate may vary based on protocols (refer to specific protocols)</p>
<p style="text-indent:-2em;margin-left:4em;">IV infusion (intermittent or continuous): Infusion rate may vary based on protocol (refer to specific protocol for infusion rate); usually over 15 to 60 minutes; larger doses (&gt;1,800 mg/m<sup>2</sup>) have been infused over 1 to 6 hours by some centers and protocols</p>
<p style="text-indent:-2em;margin-left:2em;">Bladder toxicity: To minimize bladder toxicity, increase normal fluid intake during and for 1 to 2 days after cyclophosphamide dose. Most adult patients will require a fluid intake of at least 2 L/day and in pediatric patients twice maintenance (3 L/m<sup>2</sup>/day). High-dose regimens and depending upon the protocol some standard (low) cyclophosphamide doses should be accompanied by vigorous hydration with mesna therapy (refer to specific protocols and Mesna monograph for additional information). Morning administration may be preferred to ensure adequate hydration throughout the day.</p></div>
<div class="block adm drugH1Div" id="F155430"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Cyclophosphamide is associated with a moderate or high emetic potential (depending on dose, regimen, or administration route); antiemetics may be recommended to prevent nausea and vomiting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32658626','lexi-content-ref-27664248']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32658626','lexi-content-ref-27664248'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infusion rate may vary based on protocol (refer to specific protocol for infusion rate). Administer by direct IV injection, IVPB, or continuous IV infusion. Refer to product labeling for specific information regarding reconstitution and dilution.</p>
<p style="text-indent:-2em;margin-left:4em;">Bladder toxicity: To minimize bladder toxicity, increase normal fluid intake during and for 1 to 2 days after cyclophosphamide dose. Most adult patients will require a fluid intake of at least 2 L/day. High-dose regimens should be accompanied by vigorous hydration with or without mesna therapy. Morning administration may be preferred to ensure adequate hydration throughout the day.</p>
<p style="text-indent:-2em;margin-left:4em;">Hematopoietic cell transplant (off-label use): Approaches to reduction of hemorrhagic cystitis include infusion of 0.9% NaCl 3 L/m<sup>2</sup>/24 hours, infusion of 0.9% NaCl 3 L/m<sup>2</sup>/24 hours with continuous 0.9% NaCl bladder irrigation 300 to 1000 mL/hour, and infusion of 0.9% NaCl 1.5 to 3 L/m<sup>2</sup>/24 hours with intravenous mesna. Hydration should begin at least 4 hours before cyclophosphamide and continue at least 24 hours after completion of cyclophosphamide. The daily mesna dose (as a percentage of cyclophosphamide dose) may vary; refer to protocol and/or primary literature for mesna dose. Mesna can be administered as a continuous 24-hour intravenous infusion or be given in divided doses every 4 hours. Mesna should begin at the start of treatment, and continue at least 24 hours following the last dose of cyclophosphamide.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Swallow whole; do not crush or chew; do not open capsules. To minimize bladder toxicity, increase normal fluid intake. Morning administration may be preferred to ensure adequate hydration throughout the day; do not administer at bedtime. Avoid exposure to broken capsules and tablets; if contact occurs, wash hands immediately and thoroughly.</p></div>
<div class="block hazard drugH1Div" id="F49130947"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 1]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p></div>
<div class="block sts drugH1Div" id="F155448"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Injection: Storage time may vary by product; refer to individual product labeling for details. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p>
<p style="text-indent:-2em;margin-left:4em;">Powder for reconstitution: Store intact vials of powder at ≤25°C (77°F). Exposure to excessive temperatures during transport or storage may cause active ingredient to melt (vials with melting may have a clear to yellow viscous liquid which may appear as droplets); do not use vials with signs of melting. Solutions reconstituted in sterile water for injection should be further diluted immediately. According to the manufacturer, reconstituted solutions in NS are stable for 24 hours at room temperature and for 6 days refrigerated at 2°C to 8°C (36°F to 46°F). Solutions diluted for infusion in <sup>1</sup>/<sub>2</sub>NS are stable for 24 hours at room temperature and for 6 days refrigerated and solutions diluted in D5W or D5NS are stable for 24 hours at room temperature and for 36 hours refrigerated (according to product labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">Multi-dose solution: Store intact vials at 2°C to 8°C (36°F to 46°F). Solutions diluted for infusion (20 mg/mL or 2 mg/mL concentration) may be stored for up to 48 hours at room temperature or for up to 12 days at 2°C to 8°C (36°F to 46°F) (Cyclophosphamide prescribing information [Eugia]) or up to 24 hours at room temperature or for up to 6 days at 2°C to 8°C (36°F to 46°F) (Cyclophosphamide prescribing information [Ingenus]). After first use, partially used vials should be stored at 2°C to 8°C (36°F to 46°F) in the original carton and used within 28 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Single-dose solution: Store intact vials at 2°C to 8°C (36°F to 46°F). Vials diluted with SWFI may be stored at room temperature or in the refrigerator for up to 24 hours. Vials diluted with NS (20 mg/mL) may be stored at room temperature for up to 24 hours or for up to 6 days refrigerated (Cyclophosphamide prescribing information [Dr. Reddy's Laboratories]). Infusion solutions diluted in <sup>1</sup>/<sub>2</sub>NS are stable for up to 24 hours at room temperature or for up to 6 days refrigerated. Infusion solutions diluted in D5W or D5NS are stable for up to 24 hours at room temperature or for up to 36 hours refrigerated.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules, tablets: Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).</p></div>
<div class="block usep drugH1Div" id="F53566287"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oncologic uses:</b> Treatment of Hodgkin lymphoma, non-Hodgkin lymphomas (including Burkitt lymphoma), chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute lymphocytic leukemia (ALL), mycosis fungoides, multiple myeloma, neuroblastoma, retinoblastoma, breast cancer, ovarian adenocarcinoma [Oral, parenteral: All indications: FDA approved in pediatric patients (age not specified) and adults]; has also been used for Ewing sarcoma, rhabdomyosarcoma, Wilms tumor, ovarian germ cell tumors, small cell lung cancer, testicular cancer, pheochromocytoma, CNS tumors, and in hematopoietic stem cell transplant (HSCT) conditioning regimens.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nononcologic uses:</b> Treatment of minimal change nephrotic syndrome [Oral: FDA approved in pediatric patients (age not specified)]; has also been used for treatment of aplastic anemia, lupus nephritis, uveitis, vasculitis (ANCA positive, eg, granulomatosis with polyangiitis [GPA]; Wegener granulomatosis) and Kawasaki Disease refractory to IVIG.</p></div>
<div class="block mst drugH1Div" id="F155519"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">CycloPHOSphamide may be confused with cycloSERINE, cycloSPORINE, ifosfamide</p>
<p style="text-indent:-2em;margin-left:4em;">Cytoxan may be confused with cefOXitin, Ciloxan, cytarabine, CytoGam, Cytosar, Cytosar-U, Cytotec</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F155504"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2B6 (major), CYP2C19 (minor), CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F155420"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Allopurinol: May increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: CycloPHOSphamide may enhance the adverse/toxic effect of Amiodarone. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anthracyclines: CycloPHOSphamide may enhance the cardiotoxic effect of Anthracyclines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithymocyte Globulin (Equine): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Antithymocyte Globulin (Equine). Specifically, these effects may be unmasked if the dose of cytotoxic chemotherapy is reduced. Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Antithymocyte Globulin (Equine). Specifically, infections may occur with greater severity and/or atypical presentations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AzaTHIOprine: May enhance the hepatotoxic effect of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Baricitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Baricitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Products: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of BCG Products. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of BCG Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brincidofovir: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Brincidofovir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivudine: May enhance the adverse/toxic effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BUPivacaine: CycloPHOSphamide may enhance the adverse/toxic effect of BUPivacaine. Specifically, the risk of methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chikungunya Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Chikungunya Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Chikungunya Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Cladribine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Coccidioides immitis Skin Test: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the diagnostic effect of Coccidioides immitis Skin Test.  Management: Consider discontinuing cytotoxic chemotherapy several weeks prior to coccidioides immitis skin antigen testing to increase the likelihood of accurate diagnostic results.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">COVID-19 Vaccines: CycloPHOSphamide may diminish the therapeutic effect of COVID-19 Vaccines.  Management: Adjust timing of intravenous cyclophosphamide so that administration occurs 1 week after each vaccine dose, if feasible; hold oral cyclophosphamide for 1 to 2 weeks after vaccine administration as permitted by the underlying disease.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CycloPHOSphamide may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2B6 Inducers (Moderate): May increase serum concentrations of the active metabolite(s) of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone.  Management: Avoid the concomitant use of deferiprone and myelosuppressive agents whenever possible. If this combination cannot be avoided, monitor the absolute neutrophil count more closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dengue Tetravalent Vaccine (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Dengue Tetravalent Vaccine (Live). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Dengue Tetravalent Vaccine (Live). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Denosumab: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy). Management: Consider the risk of serious infections versus the potential benefits of coadministration of denosumab and cytotoxic chemotherapy. If combined, monitor patients for signs/symptoms of serious infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deucravacitinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etanercept: May enhance the adverse/toxic effect of CycloPHOSphamide. An increased risk of solid cancer development may be present.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Myelosuppressive Agents may enhance the myelosuppressive effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgotinib: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Filgrastim: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, the risk of pulmonary toxicity may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluconazole: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, serum bilirubin and serum creatinine may be increased. Fluconazole may increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inebilizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Inebilizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Influenza Virus Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Influenza Virus Vaccines.  Management: Administer influenza vaccines at least 2 weeks prior to initiating chemotherapy if possible. If vaccination occurs less than 2 weeks prior to or during chemotherapy, revaccinate at least 3 months after therapy discontinued if immune competence restored.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, serum creatinine and serum bilirubin may be increased. Itraconazole may increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Leflunomide.  Management: Increase the frequency of chronic monitoring of platelet, white blood cell count, and hemoglobin or hematocrit to monthly, instead of every 6 to 8 weeks, if leflunomide is coadministered with immunosuppressive agents, such as cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenograstim: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, the risk of pulmonary toxicity may be enhanced. CycloPHOSphamide may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Monitor for enhanced pulmonary toxicity when cyclophosphamide and lenograstim are given in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipegfilgrastim: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, the risk of pulmonary toxicity may be increased. CycloPHOSphamide may diminish the therapeutic effect of Lipegfilgrastim. Management: Lipegfilgrastim should be administered at least 24 hours after the completion of cyclophosphamide. Consider monitoring for enhanced pulmonary toxicity when cyclophosphamide and lipegfilgrastim are given in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: CycloPHOSphamide may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mumps- Rubella- or Varicella-Containing Live Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nadofaragene Firadenovec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Nadofaragene Firadenovec. Specifically, the risk of disseminated adenovirus infection may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Natalizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Natalizumab. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitric Oxide: May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ocrelizumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ocrelizumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ofatumumab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ofatumumab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: Myelosuppressive Agents may enhance the myelosuppressive effect of Olaparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pidotimod: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pneumococcal Vaccines: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Pneumococcal Vaccines. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Poliovirus Vaccine (Live/Trivalent/Oral): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Poliovirus Vaccine (Live/Trivalent/Oral). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Poliovirus Vaccine (Live/Trivalent/Oral). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymethylmethacrylate: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the potential for allergic or hypersensitivity reactions to Polymethylmethacrylate.  Management: Use caution when considering use of bovine collagen-containing implants such as the polymethylmethacrylate-based Bellafill brand implant in patients who are receiving immunosuppressants. Consider use of additional skin tests prior to administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, the incidences of neutropenia, infection, and mucositis may be increased. Protease Inhibitors may increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Rabies Vaccine.  Management: Complete rabies vaccination at least 2 weeks before initiation of immunosuppressant therapy if possible. If combined, check for rabies antibody titers, and if vaccination is for post exposure prophylaxis, administer a 5th dose of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ritlecitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ropeginterferon Alfa-2b: Myelosuppressive Agents may enhance the myelosuppressive effect of Ropeginterferon Alfa-2b.  Management: Avoid coadministration of ropeginterferon alfa-2b and other myelosuppressive agents. If this combination cannot be avoided, monitor patients for excessive myelosuppressive effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ruxolitinib (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sargramostim: CycloPHOSphamide may enhance the adverse/toxic effect of Sargramostim. Specifically, the risk of pulmonary toxicity may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Schisandra: May increase the serum concentration of CycloPHOSphamide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sipuleucel-T: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Sipuleucel-T.  Management: Consider reducing the dose or discontinuing the use of immunosuppressants, such as cytotoxic chemotherapy, prior to initiating sipuleucel-T therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sphingosine 1-Phosphate (S1P) Receptor Modulator: May enhance the immunosuppressive effect of Immunosuppressants (Cytotoxic Chemotherapy).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: CycloPHOSphamide may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days. If combined, consider reduced succinylcholine doses and close monitoring for increased and prolonged neuromuscular blocking effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tacrolimus (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talimogene Laherparepvec: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Talimogene Laherparepvec. Specifically, the risk of infection from the live, attenuated herpes simplex virus contained in talimogene laherparepvec may be increased. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tertomotide: Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Tertomotide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of CycloPHOSphamide. Specifically, granulocytopenia may be enhanced.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: May increase the serum concentration of CYP2B6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Typhoid Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Typhoid Vaccine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ublituximab: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Ublituximab. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the immunosuppressive effect of Upadacitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Inactivated/Non-Replicating): Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Vaccines (Inactivated/Non-Replicating).  Management: Give inactivated vaccines at least 2 weeks prior to initiation of chemotherapy when possible. Patients vaccinated less than 14 days before initiating or during chemotherapy should be revaccinated at least 3 months after therapy is complete.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Vaccines (Live) may diminish the therapeutic effect of Immunosuppressants (Cytotoxic Chemotherapy). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CycloPHOSphamide may enhance the adverse/toxic effect of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Yellow Fever Vaccine: Immunosuppressants (Cytotoxic Chemotherapy) may enhance the adverse/toxic effect of Yellow Fever Vaccine. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Yellow Fever Vaccine. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49296864"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Evaluate pregnancy status prior to use in patients who could become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Patients who could become pregnant should use effective contraception while receiving cyclophosphamide and for up to 1 year after completion of cyclophosphamide treatment. Patients with partners who are or could become pregnant should use a condom during and for at least 4 months after cyclophosphamide treatment.</p>
<p style="text-indent:0em;margin-top:2em;">Cyclophosphamide is used off label in the management of lupus nephritis in nonpregnant adults (ACR [Hahn 2012]; EULAR/ERA-EDTA [Fanouriakis 2020]). Patients treated for rheumatic and musculoskeletal diseases should consider discontinuing cyclophosphamide 3 to 6 months prior to conception to allow for disease monitoring and potential change to another immunosuppressant. Cyclophosphamide should also be discontinued 12 weeks prior to attempted conception in patients with rheumatic and musculoskeletal diseases who are planning to father a child (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Cyclophosphamide may cause ovarian insufficiency, and infertility and long-term gonadal damage. Dose-related sterility (which may be irreversible) may occur in all patients. Recommendations are available for fertility preservation of adult patients treated with anticancer agents (ASCO [Oktay 2018]). Recommendations for preserving fertility in patients treated with cyclophosphamide for autoimmune and systemic inflammatory diseases are available (ACR [Sammaritano 2020]).</p></div>
<div class="block pri drugH1Div" id="F13494887"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cyclophosphamide crosses the placenta and can be detected in amniotic fluid (D'Incalci 1982).</p>
<p style="text-indent:0em;margin-top:2em;">Birth defects (including malformations of the skeleton, palate, limbs, and eyes), miscarriage, fetal growth retardation, and fetotoxic effects in the newborn (including anemia, gastroenteritis leukopenia, pancytopenia, and severe bone marrow hypoplasia) have been reported.</p>
<p style="text-indent:0em;margin-top:2em;">Cyclophosphamide, if indicated, may be administered to pregnant patients with breast cancer as part of some combination chemotherapy regimens; chemotherapy should not be administered during the first trimester, after 35 weeks' gestation, or within 3 weeks of planned delivery (Amant 2010; Loibl 2015; Shachar 2017). Use of regimens containing cyclophosphamide are generally avoided for the treatment of Hodgkin or non-Hodgkin lymphoma in pregnancy. However, use of cyclophosphamide may be considered as part of some regimens to treat patients diagnosed with aggressive non-Hodgkin lymphomas during the second or third trimester (Lishner 2016; Moshe 2017). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) approach. In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">Cyclophosphamide is used off label in the management of lupus nephritis in nonpregnant adults (ACR [Hahn 2012]; EULAR/ERA-EDTA [Fanouriakis 2020). In patients with life- or organ-threatening maternal disease, cyclophosphamide may be used in the second or third trimesters only when an alternative therapy is not available (ACR [Sammaritano 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">A long-term observational research study is collecting information about the diagnosis and treatment of cancer during pregnancy. For additional information about the pregnancy and cancer registry or to become a participant, contact Cooper Health (877-635-4499).</p></div>
<div class="block mopp drugH1Div" id="F53566289"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">CBC with differential and platelet count, BUN, urinalysis, urine specific gravity, urine output, serum electrolytes, serum creatinine, monitor for signs/symptoms of hemorrhagic cystitis or other urinary/renal toxicity, pulmonary, cardiac, and/or hepatic toxicity.</p></div>
<div class="block pha drugH1Div" id="F155414"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.</p></div>
<div class="block phk drugH1Div" id="F155433"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Oral: Well absorbed </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: V<sub>d</sub>: 30 to 50 L (approximates total body water); crosses into CSF (not in high enough concentrations to treat meningeal leukemia) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~20%; some metabolites are bound at &gt;60% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic to active metabolites acrolein, 4-aldophosphamide, 4-hydroperoxycyclophosphamide, and nor-nitrogen mustard</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: &gt;75% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: IV: 3 to 12 hours; Children: 4 hours; Adults: 6 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak: Oral: ~1 hour; IV: Metabolites: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (10 to 20% as unchanged drug); feces (4%) </p></div>
<div class="block phksp drugH1Div" id="F51220867"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Systemic exposure is increased as renal function declines. The mean (dose-corrected AUC) increased by 38% in patients with moderate renal impairment (CrCl 25 to 50 mL/minute), increased by 64% in patients with severe impairment (CrCl 10 to 24 mL/minute), and by 23% in patients undergoing hemodialysis (CrCl &lt;10 mL/minute), when compared to a control group.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with severe hepatic impairment, the elimination half-life is prolonged by 64%.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F155439"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Ciclofosfamida filaxis | Ciclofosfamida gp pharm | Ciclofosfamida kemex | Ciclofosfamida LKM | Ciclofosfamida martian | Ciclofosfamida microsules | Ciclokebir | Endoxan Asta | Genoxal</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid sandoz | Endoxan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Cycloblastin | Cyclonex | Endoxan</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cycloblastine | Cyclophosphamide sandoz | Endoxan</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphan | Cytoxan | Endoxan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Genuxal</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid farmos | Endoxan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Cytoxan | Endoxan | Formitex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cyclostin | Cytoxan | Endoxan | Syklofosfamid</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cyclo cell | Cyclophosphamid | Cyclophosphamid hexal | Endoxan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Neophos</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Cycram | Endoxan | Formitex</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphan | Cytoxan | Endoxan | Syklofosfamid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cycram | Endoxan</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Genoxal</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Uniphos</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sendoxan | Syklofosfamid</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamide Dci | Cyclophosphamide reddy pharma | Cyclophosphamide sandoz | Endoxan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cyclophospham | Endoxana | Trav cyclophosphamide</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cyclophosphamid sandoz | Cytoxan | Endoxan</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cyclovid | Endoxan | Neosar</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Endoxana</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Cytophosphan | Cytoxan | Endoxan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Chophos | Cyclocel | Cycloway | Cycloxan | Cycram | Cydoxan | Endoxan | Endoxan-n | Ledoxan | Oncomide | Oncophos | Phosmid | Phoxelon | Uniphos | Zuviphos</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Cycloxan | Cyphos | Oncomide</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alkyloxan | Ckd cyclophosphamide | Cyclam | Cycram | Cyphamid | Cytoxan | Endoxan | Endoxan Asta | Neophamid | Union cyclophosphamide</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cyclophosphan | Cyclostin | Endoxan | Ledoxina</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Cycloblastine | Endoxan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cyclophosphan | Cyclostin | Endoxan</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Cryofaxol | Cycloxan | Endoxan | Formitex | Genoxal | Hidrofosmin | Ledoxina | Mexcikem</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Alkyloxan | Cycloxan | Endoxan | Ledoxan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cyclofosfamide Sandoz | Endoxan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cyklofosfamid | Procytox | Sendoxan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Cycloblastin | Cyclonex | Cytoxan | Endoxan | Endoxan Asta | Procytox</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ciclobif | Ciclofosfamida | Cytoxan</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Biomedis cyclophosphamide | Cyclomet | Cyclophar | Cyclophos | Cyphocare | Cyphos | Cytoxan | Endoxan | Glotoxan | Ledoxan | Xyclomed</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Cyclomide | Endoxan | Oncofos | Zycram</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cytoxan | Endoxan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cytoxan | Cytoxan lyophilized | Neosar</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Endoxan</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida kemex | Ciclofosfamida martian | Ciclofosfamida microsules</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Endoxan</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cyclophocil | Cyclophosphamide instant | Cyclophosphamide teva | Cyclophosphamide-lens instant | Cyclophosphan | Cyclophosphan lens | Cyclophosphan lens instant | Cytoxan | Endoxan | Ledoxina</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cyklofosfamid | Sendoxan</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Alkyloxan | Endoxan</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Alkyloxan | Cycloblastin | Cyclomide | Cycloxan | Endoxan | Ledoxan | Oncomide</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Endoxan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Alkyloxan | Endoxan | Syklofosfamid</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cytoxan | Endoxan | Endoxan Asta | Syklofosfamid</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Cyclophosphamid | Cyclophosphan | Endoxan</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Ciclofosfamida | Ciclofosfamida filaxis | Cysmide | Endoxan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biodoxan | Neophos</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Cycloblastin | Endoxan</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Cycloxan | Oncomide</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  &lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11429481">
<a name="11429481"></a>Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. <i>Curr Opin Oncol</i>. 2001;13(4):242-248. doi:10.1097/00001622-200107000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11429481/pubmed" id="11429481" target="_blank">11429481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32888407">
<a name="32888407"></a>Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet</i>. 2020;396(10254):839-852. doi:10.1016/S0140-6736(20)31366-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32888407/pubmed" id="32888407" target="_blank">32888407</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25403681">
<a name="25403681"></a>ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. <i>Arthritis Rheumatol</i>. 2014;66(11):3096-3104. doi:10.1002/art.38790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25403681/pubmed" id="25403681" target="_blank">25403681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16294218">
<a name="16294218"></a>Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. <i>Nat Rev Cancer</i>. 2005;5(12):943-955. doi:10.1038/nrc1749<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16294218/pubmed" id="16294218" target="_blank">16294218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27821390">
<a name="27821390"></a>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. <i>Clin J Am Soc Nephrol</i>. 2017;12(5):825-835. doi:10.2215/CJN.05780616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27821390/pubmed" id="27821390" target="_blank">27821390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20932740">
<a name="20932740"></a>Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. <i>Eur J Cancer</i>. 2010;46(18):3158-3168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20932740/pubmed" id="20932740" target="_blank">20932740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26446832">
<a name="26446832"></a>American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26446832/pubmed" id="26446832" target="_blank">26446832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8558201">
<a name="8558201"></a>Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total body-irradiation and analysis of prognostic factors. <i>J Clin Oncol.</i> 1996;14(1):220-226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8558201/pubmed" id="8558201" target="_blank">8558201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15143082">
<a name="15143082"></a>Arndt C, Hawkins, D, Anderson JR, et al. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin and cyclophosphamide.<i> J Clin Oncol.</i> 2004;22(10):1894-1901.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15143082/pubmed" id="15143082" target="_blank">15143082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19770373">
<a name="19770373"></a>Arndt CA, Stoner JA, Hawkins DS, et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. <i>J Clin Oncol</i>. 2009;27(31):5182-5188. doi: 10.1200/JCO.2009.22.3768.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19770373/pubmed" id="19770373" target="_blank">19770373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. American College of Physicians; 2007, p 97, 170.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8977704">
<a name="8977704"></a>Assier-Bonnet H, Aractingi S, Cadranel J, Wechsler J, Mayaud C, Saiag P. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. <i>Br J Dermatol</i>. 1996;135(5):864-866. doi:10.1111/j.1365-2133.1996.tb03915.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8977704/pubmed" id="8977704" target="_blank">8977704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19827142">
<a name="19827142"></a>Audino AN, Blatt J, Carcamo B, et.al. High-dose cyclophosphamide treatment for refractory severe aplastic anemia in children. <i>Pediatr Blood Cancer</i>. 2010;54:269-272.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19827142/pubmed" id="19827142" target="_blank">19827142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3511372">
<a name="3511372"></a>Austin HA 3rd, Klipel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs <i>N Engl J Med. </i> 1986;314(10):614-619.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/3511372/pubmed" id="3511372" target="_blank">3511372</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29276769">
<a name="29276769"></a>Banerjee S, Biehl A, Ghaderi-Yeganeh M, Manna Z, Hasni S. Low incidence of opportunistic infections in lupus patients treated with cyclophosphamide and steroids in a tertiary care setting. <i>Med Res Arch</i>. 2017;5(3):10.18103/mra.v5i3.1084. doi:10.18103/mra.v5i3.1084<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29276769/pubmed" id="29276769" target="_blank">29276769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33568350">
<a name="33568350"></a>Beattie J, Rizvi H, Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. <i>J Immunother Cancer</i>. 2021;9(2):e001884. doi:10.1136/jitc-2020-001884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33568350/pubmed" id="33568350" target="_blank">33568350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16099877">
<a name="16099877"></a>Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. <i>Blood</i>. 2005;106(10):3343-3347.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16099877/pubmed" id="16099877" target="_blank">16099877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34175021">
<a name="34175021"></a>Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. <i>Lancet</i>. 2021;398(10297):314-324. doi:10.1016/S0140-6736(21)00933-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34175021/pubmed" id="34175021" target="_blank">34175021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19452540">
<a name="19452540"></a>Berger M, Grignani G, Ferrari S, et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high-risk osteosarcoma patients. <i>Cancer</i>. 2009;115(13):2980-2987. doi:10.1002/cncr.24368<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19452540/pubmed" id="19452540" target="_blank">19452540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berns.1">
<a name="Berns.1"></a>Berns JS. Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22851469">
<a name="22851469"></a>Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Ann Rheum Dis</i>. 2012;71(11):1771-1782.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22851469/pubmed" id="22851469" target="_blank">22851469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24565993">
<a name="24565993"></a>Bodge MN, Reddy S, Thompson MS, Savani BN. Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. <i>Biol Blood Marrow Transplant</i>. 2014;20(7):908-919. doi:10.1016/j.bbmt.2014.02.013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24565993/pubmed" id="24565993" target="_blank">24565993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2045862">
<a name="2045862"></a>Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. <i>J Clin Oncol</i>. 1991;9(7):1215-1223. doi:10.1200/JCO.1991.9.7.1215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2045862/pubmed" id="2045862" target="_blank">2045862</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20018919">
<a name="20018919"></a>Brodsky RA, Chen AR, Dorr D, et.al. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. <i>Blood</i>. 2010;115:2136-2141.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20018919/pubmed" id="20018919" target="_blank">20018919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8555470">
<a name="8555470"></a>Brodsky RA, Sensenbrenner LL, Jones RJ. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. <i>Blood</i>. 1996;87(2): 491-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8555470/pubmed" id="8555470" target="_blank">8555470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15753460">
<a name="15753460"></a>Brown JR, Yeckes H, Friedberg JW, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. <i>J Clin Oncol</i>. 2005;23(10):2208-2214. doi:10.1200/JCO.2005.05.158<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15753460/pubmed" id="15753460" target="_blank">15753460</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24462742">
<a name="24462742"></a>Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24462742/pubmed" id="24462742" target="_blank">24462742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17138821">
<a name="17138821"></a>Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. <i>Blood</i>. 2007;109(7):2736-2743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17138821/pubmed" id="17138821" target="_blank">17138821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16079934">
<a name="16079934"></a>Cakir O, Ayyildiz O, Isikdogan A. Type III mixed cryoglobulinemia associated with digital necrotic ulcer successfully treated with intermittent intravenous pulse cyclophosphamide--a case report. <i>Angiology</i>. 2005;56(4):489-492. doi:10.1177/000331970505600418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16079934/pubmed" id="16079934" target="_blank">16079934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8426209">
<a name="8426209"></a>Cassileth PA, Andersen J, Lazarus HM, et al. Autologous Bone Marrow Transplant in Acute Myeloid Leukemia in First Remission. <i>J Clin Oncol.</i> 1993;11(2):314-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8426209/pubmed" id="8426209" target="_blank">8426209</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9834301">
<a name="9834301"></a>Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. <i>N Engl J Med</i>. 1998;339(23):1649-1656. doi:10.1056/NEJM199812033392301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9834301/pubmed" id="9834301" target="_blank">9834301</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17272503">
<a name="17272503"></a>Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. <i>Blood.</i> 2007;109(10):4582-4585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17272503/pubmed" id="17272503" target="_blank">17272503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12518344">
<a name="12518344"></a>Chantada G, Fandiño A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. <i>Med Pediatr Oncol</i>. 2003;40(3):158-161.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12518344/pubmed" id="12518344" target="_blank">12518344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2207307">
<a name="2207307"></a>Chao NJ, Rosenberg SA, Horning SJ. CEPP(B): an effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. <i>Blood</i>. 1990;76(7):1293-1298.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2207307/pubmed" id="2207307" target="_blank">2207307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33235058">
<a name="33235058"></a>Chen J, Jin Y, Li C, Li Z. Symptomatic hyponatremia induced by low-dose cyclophosphamide in patient with systemic lupus erythematosus: a case report. <i>Medicine (Baltimore)</i>. 2020;99(48):e22498. doi:10.1097/MD.0000000000022498<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33235058/pubmed" id="33235058" target="_blank">33235058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15611503">
<a name="15611503"></a>Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15611503/pubmed" id="15611503" target="_blank">15611503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34134927">
<a name="34134927"></a>Chou WH, McGregor B, Schmidt A, et al. Cyclophosphamide-associated bladder cancers and considerations for survivorship care: a systematic review. <i>Urol Oncol</i>. 2021;39(10):678-685. doi:10.1016/j.urolonc.2021.05.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34134927/pubmed" id="34134927" target="_blank">34134927</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235889">
<a name="34235889"></a>Chung SA, Gorelik M, Langford CA, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa.<i> Arthritis Care Res (Hoboken).</i> 2021b;73(8):1061-1070. doi:10.1002/acr.24633<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34235889/pubmed" id="34235889" target="_blank">34235889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34235894">
<a name="34235894"></a>Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Rheumatol</i>. 2021a;73(8):1366-1383. doi:10.1002/art.41773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34235894/pubmed" id="34235894" target="_blank">34235894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25974382">
<a name="25974382"></a>Cibeira MT, Oriol A, Lahuerta JJ, et al; PETHEMA cooperative study group. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. <i>Br J Haematol</i>. 2015;170(6):804-813. doi:10.1111/bjh.13500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25974382/pubmed" id="25974382" target="_blank">25974382</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31437753">
<a name="31437753"></a>Codacci-Pisanelli G, Honeywell RJ, Asselin N, et al. Breastfeeding during R-CHOP chemotherapy: please abstain! <i>Eur J Cancer</i>. 2019;119:107-111. doi:0.1016/j.ejca.2019.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/31437753/pubmed" id="31437753" target="_blank">31437753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17471546">
<a name="17471546"></a>Cohen P, Pagnoux C, Mahr A, et al; French Vasculitis Study Group. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. <i>Arthritis Rheum</i>. 2007;57(4):686-693. doi:10.1002/art.22679<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17471546/pubmed" id="17471546" target="_blank">17471546</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11807147">
<a name="11807147"></a>Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. <i>N Engl J Med. </i>2002;346(4):235-242.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11807147/pubmed" id="11807147" target="_blank">11807147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18338745">
<a name="18338745"></a>Coleman M, Martin P, Ruan J, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. <i>Cancer</i>. 2008;112(10):2228-2232. doi:10.1002/cncr.23422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18338745/pubmed" id="18338745" target="_blank">18338745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9048121">
<a name="9048121"></a>Copper JA Jr. Drug-induced lung disease. <i>Adv Intern Med</i>. 1997;42:231-268.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9048121/pubmed" id="9048121" target="_blank">9048121</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11756155">
<a name="11756155"></a>Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. <i>Blood</i>. 2002;99(1):75-82. doi:10.1182/blood.v99.1.75<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11756155/pubmed" id="11756155" target="_blank">11756155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20560293">
<a name="20560293"></a>Corte TJ, Ellis R, Renzoni EA, et al. Use of intravenous cyclophosphamide in known or suspected, advanced non-specific interstitial pneumonia. <i>Sarcoidosis Vasc Diffuse Lung Dis</i>. 2009;26(2):132-138.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20560293/pubmed" id="20560293" target="_blank">20560293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ANI.1">
<a name="ANI.1"></a>Cyclophosphamide capsules [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingenus.1">
<a name="Ingenus.1"></a>Cyclophosphamide injection, multi-dose vial [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals; September 2021.</div>
</li>
<li>
<div class="reference">
                  Cyclophosphamide injection, multi-dose vial [prescribing information]. E. Windsor, NJ: Eugia US LLC; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AuroMedics.1">
<a name="AuroMedics.1"></a>Cyclophosphamide injection, single-dose vial [prescribing information]. E. Windsor, NJ: AuroMedics Pharma LLC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DrReddy.1">
<a name="DrReddy.1"></a>Cyclophosphamide injection, single-dose vial [prescribing information]. Princeton, NJ: Dr. Reddy’s Laboratories Inc; June 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BluePoint.1">
<a name="BluePoint.1"></a>Cyclophosphamide injection [prescribing information]. BluePoint Laboratories; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baxter.1">
<a name="Baxter.1"></a>Cyclophosphamide tablets [prescribing information]. Baxter Healthcare Corporation; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25071139">
<a name="25071139"></a>Dal Pra A, Berlin A, Kumareswaran R, et al. Liver failure after abdominal irradiation: identifying the right suspects. <i>J Clin Oncol</i>. 2016;34(9):e80-e83. doi:10.1200/JCO.2013.50.9547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25071139/pubmed" id="25071139" target="_blank">25071139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19451574">
<a name="19451574"></a>de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. <i>Ann Intern Med.</i> 2009;150(10):670-680.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19451574/pubmed" id="19451574" target="_blank">19451574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DeVriese.1">
<a name="DeVriese.1"></a>De Vriese AS, Wetzels JFM, Cattran DC. Membranous nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 28, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28369839">
<a name="28369839"></a>DeFilipp Z, Li S, El-Jawahri A, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. <i>Cancer</i>. 2017;123(16):3073-3079. doi:10.1002/cncr.30695<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28369839/pubmed" id="28369839" target="_blank">28369839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dellaripa.1">
<a name="Dellaripa.1"></a>Dellaripa PF, Danoff SK. Interstitial lung disease in dermatomyositis and polymyositis: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 16, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21358440">
<a name="21358440"></a>DeZern AE, Petri M, Drachman DB, et al. High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases. <i>Medicine</i>. 2011;90:89-98.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21358440/pubmed" id="21358440" target="_blank">21358440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25542311">
<a name="25542311"></a>Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25542311/pubmed" id="25542311" target="_blank">25542311</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26425570">
<a name="26425570"></a>Dhesi S, Chu MP, Blevins G, et al. Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management. <i>J Investig Med High Impact Case Rep</i>. 2013;1(1):2324709613480346. doi:10.1177/2324709613480346<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26425570/pubmed" id="26425570" target="_blank">26425570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12802024">
<a name="12802024"></a>Diehl V, Franklin J, Pfreundschuh M, et al. Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's disease. <i>N Engl J Med.</i> 2003;348(24):2386-2395.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12802024/pubmed" id="12802024" target="_blank">12802024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17577016">
<a name="17577016"></a>Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. <i>J Clin Oncol</i>. 2007;25(22):3344-3349. doi: 10.1200/JCO.2007.10.9926.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17577016/pubmed" id="17577016" target="_blank">17577016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26976420">
<a name="26976420"></a>Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment. <i>J Clin Oncol</i>. 2016;34(13):1544-1557. doi:10.1200/JCO.2015.65.0044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26976420/pubmed" id="26976420" target="_blank">26976420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7105061">
<a name="7105061"></a>D'Incalci M, Sessa C, Colombo N, et al. Transplacental passage of cyclophosphamide. <i>Cancer Treat Rep</i>. 1982;66(8):1681-1682.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7105061/pubmed" id="7105061" target="_blank">7105061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dine.1">
<a name="Dine.1"></a>Dine T, Lebegue S, Benaji B, et al. Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags. <i>Pharm Sci Communications.</i> 1994;4:97-101.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14993502">
<a name="14993502"></a>du Buf-Vereijken PW, Branten AJ, Wetzels JF; Membranous Nephropathy Study Group. Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate. <i>Nephrol Dial Transplant</i>. 2004;19(5):1142-1148. doi:10.1093/ndt/gfh036<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/14993502/pubmed" id="14993502" target="_blank">14993502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23574119">
<a name="23574119"></a>Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. <i>N Engl J Med</i>. 2013;368(15):1408-1416. doi:10.1056/NEJMoa1214561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23574119/pubmed" id="23574119" target="_blank">23574119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512831">
<a name="23512831"></a>Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23512831/pubmed" id="23512831" target="_blank">23512831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21465637">
<a name="21465637"></a>Dupuis LL, Boodhan S, Sung L. Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients. <i>Pediatr Blood Cancer.</i> 2011;57(2):191-198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21465637/pubmed" id="21465637" target="_blank">21465637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-423292">
<a name="423292"></a>Durodola JI. Administration of cyclophosphamide during late pregnancy and early lactation: a case report. <i>J Natl Med Assoc</i>. 1979;71(2):165-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/423292/pubmed" id="423292" target="_blank">423292</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33384141">
<a name="33384141"></a>Eiriksson L, Dean E, Sebastianelli A, et al. Guideline No. 408: management of gestational trophoblastic diseases. <i>J Obstet Gynaecol Can</i>. 2021;43(1):91-105.e1. doi:10.1016/j.jogc.2020.03.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33384141/pubmed" id="33384141" target="_blank">33384141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14675675">
<a name="14675675"></a>Escobar PF, Lurain JR, Singh DK, et al. Treatment of High-Risk Gestational Trophoblastic Neoplasia With Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide, and Vincristine Chemotherapy. <i>Gynecol Oncol.</i> 2003;91(3):552-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/14675675/pubmed" id="14675675" target="_blank">14675675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28729970">
<a name="28729970"></a>Esposito P, Domenech MV, Serpieri N, et al. Severe cyclophosphamide-related hyponatremia in a patient with acute glomerulonephritis. <i>World J Nephrol</i>. 2017;6(4):217-220. doi:10.5527/wjn.v6.i4.217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28729970/pubmed" id="28729970" target="_blank">28729970</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fajgenbaum.2020">
<a name="Fajgenbaum.2020"></a>Fajgenbaum DC. HHV-8-negative/idiopathic multicentric Castleman disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32220834">
<a name="32220834"></a>Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Ann Rheum Dis</i>. 2020;79(6):713-723. doi:10.1136/annrheumdis-2020-216924<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32220834/pubmed" id="32220834" target="_blank">32220834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Falk.1">
<a name="Falk.1"></a>Falk RJ, Dall'Era M, Appel GB. Lupus nephritis: initial and subsequent therapy for focal or diffuse lupus nephritis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Falk.2">
<a name="Falk.2"></a>Falk RJ, Merkel PA. Granulomatosis with polyangiitis and microscopic polyangiitis: management of disease resistant to initial therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9307187">
<a name="9307187"></a>Fenig E, Brenner B, Katz A, et al. The role of radiation therapy and chemotherapy in the treatment of Merkel cell carcinoma. <i>Cancer</i>. 1997;80(5):881-885. doi:10.1002/(sici)1097-0142(19970901)80:5&lt;881::aid-cncr8&gt;3.0.co;2-o<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9307187/pubmed" id="9307187" target="_blank">9307187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16707424">
<a name="16707424"></a>Fenske TS, McMahon C, Edwin D, et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. <i>Cancer Res</i>. 2006;66(10):5029-5038. doi:10.1158/0008-5472.CAN-05-3404<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16707424/pubmed" id="16707424" target="_blank">16707424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29781586">
<a name="29781586"></a>Fernández-Codina A, Walker KM, Pope JE; Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. <i>Arthritis Rheumatol</i>. 2018;70(11):1820-1828. doi:10.1002/art.40560<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29781586/pubmed" id="29781586" target="_blank">29781586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33166580">
<a name="33166580"></a>Fernández-Juárez G, Rojas-Rivera J, Logt AV, et al; STARMEN Investigators. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. <i>Kidney Int</i>. 2021;99(4):986-998. doi:10.1016/j.kint.2020.10.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33166580/pubmed" id="33166580" target="_blank">33166580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fervenza.1">
<a name="Fervenza.1"></a>Fervenza FC, Leise MD, Roccatello D. Mixed cryoglobulinemia syndrome: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 24, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2202791">
<a name="2202791"></a>Fisher B, Brown AM, Dimitrov NV, et al. Two Months of Doxorubicin-Cyclophosphamide With and Without Interval Reinduction Therapy Compared With 6 Months of Cyclophosphamide, Methotrexate, and Fluorouracil in Positive-Node Breast Cancer Patients With Tamoxifen-Nonresponsive Tumors: Results From the National Surgical Adjuvant Breast and Bowel Project B-15. <i>J Clin Oncol.</i> 1990;8(9):1483-1496.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2202791/pubmed" id="2202791" target="_blank">2202791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Flaherty.1">
<a name="Flaherty.1"></a>Flaherty KR. Treatment and prognosis of nonspecific interstitial pneumonia. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 25, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30665568">
<a name="30665568"></a>Floege J, Barbour SJ, Cattran DC, et al; Conference Participants. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2019;95(2):268-280. doi:10.1016/j.kint.2018.10.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30665568/pubmed" id="30665568" target="_blank">30665568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16473644">
<a name="16473644"></a>Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. <i>Semin Oncol.</i> 2006;33(1):50-67. doi:10.1053/j.seminoncol.2005.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16473644/pubmed" id="16473644" target="_blank">16473644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16234530">
<a name="16234530"></a>Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, Perry MC. Cardiotoxicity of Cancer Therapy. <i>J Clin Oncol.</i> 2005;23(30):7685-7696. doi:10.1200/JCO.2005.08.789<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16234530/pubmed" id="16234530" target="_blank">16234530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2049749">
<a name="2049749"></a>Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. <i>Cancer</i>. 1991;68(1):30-33. doi:10.1002/1097-0142(19910701)68:1&lt;30::aid-cncr2820680106&gt;3.0.co;2-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2049749/pubmed" id="2049749" target="_blank">2049749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1620812">
<a name="1620812"></a>Frankel AH, Singer DR, Winearls CG, Evans DJ, Rees AJ, Pusey CD. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. <i>Q J Med</i>. 1992;82(298):101-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/1620812/pubmed" id="1620812" target="_blank">1620812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25311218">
<a name="25311218"></a>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25311218/pubmed" id="25311218" target="_blank">25311218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7786253">
<a name="7786253"></a>Garas G, Crawford GP, Cain M. Anaphylactic reaction to intravenous cyclophosphamide. <i>Aust N Z J Med</i>. 1995;25(1):59. doi:10.1111/j.1445-5994.1995.tb00585.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7786253/pubmed" id="7786253" target="_blank">7786253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17233819">
<a name="17233819"></a>García-Suárez J, Bañas H, Arribas I, et al. Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. <i>Br J Haematol.</i> 2007;136(2):276-285.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17233819/pubmed" id="17233819" target="_blank">17233819</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9448590">
<a name="9448590"></a>Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. <i>Br J Rheumatol</i>. 1997;36(12):1290-1297. doi:10.1093/rheumatology/36.12.1290<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9448590/pubmed" id="9448590" target="_blank">9448590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22911342">
<a name="22911342"></a>Gilbar PJ, Richmond J, Wood J, Sullivan A. Syndrome of inappropriate antidiuretic hormone secretion induced by a single dose of oral cyclophosphamide. <i>Ann Pharmacother</i>. 2012;46(9):e23. doi:10.1345/aph.1R296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22911342/pubmed" id="22911342" target="_blank">22911342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651590">
<a name="19651590"></a>Gipson DS, Massengill SF, Yao L, et al. Management of childhood onset nephrotic syndrome. <i>Pediatrics</i>. <i>2009</i>. 124:747-757.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19651590/pubmed" id="19651590" target="_blank">19651590</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11435321">
<a name="11435321"></a>Go RS, Li CY, Tefferi A, Phyliky RL. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. <i>Blood.</i> 2001;98(2):483-485. doi:10.1182/blood.v98.2.483<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11435321/pubmed" id="11435321" target="_blank">11435321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28360039">
<a name="28360039"></a>Go RS, Winters JL, Kay NE. How I treat autoimmune hemolytic anemia. <i>Blood</i>. 2017;129(22):2971-2979. doi: 10.1182/blood-2016-11-693689.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28360039/pubmed" id="28360039" target="_blank">28360039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9653488">
<a name="9653488"></a>Goldhirsch A, Colleoni M, Coates AS, et al. Adding Adjuvant CMF Chemotherapy to Either Radiotherapy or Tamoxifen: Are All CMFs Alike? The International Breast Cancer Study Group (IBCSG). <i>Ann Oncol.</i> 1998;9(5):489-493.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9653488/pubmed" id="9653488" target="_blank">9653488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22940833">
<a name="22940833"></a>Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22940833/pubmed" id="22940833" target="_blank">22940833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25066629">
<a name="25066629"></a>Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25066629/pubmed" id="25066629" target="_blank">25066629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33657221">
<a name="33657221"></a>Goldsmith SR, Abid MB, Auletta JJ, et al. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i>. 2021;137(23):3291-3305. doi:10.1182/blood.2020009362<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33657221/pubmed" id="33657221" target="_blank">33657221</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7235784">
<a name="7235784"></a>Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J. Cardiotoxicity associated with high-dose cyclophosphamide therapy. <i>Arch Intern Med</i>. 1981;141(6):758-763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7235784/pubmed" id="7235784" target="_blank">7235784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8815753">
<a name="8815753"></a>Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. <i>Ann Intern Med.</i> 1996;125(7):549-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8815753/pubmed" id="8815753" target="_blank">8815753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7931483">
<a name="7931483"></a>Green DM, Beckwith JB, Breslow NE, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. <i>J Clin Oncol</i>. 1994;12(10):2126-2131.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7931483/pubmed" id="7931483" target="_blank">7931483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16547940">
<a name="16547940"></a>Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms Tumor Relapsing After Initial Treatment With Vincristine and Actinomycin D: A Report From the National Wilms Tumor Study Group. <i>Pediatr Blood Cancer.</i> 2007;48(5):493-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16547940/pubmed" id="16547940" target="_blank">16547940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12594313">
<a name="12594313"></a>Grier HE, Krailo MD, Tarbell NJ, et al. Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone. <i>N Engl J Med.</i> 2003;348(8):694-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12594313/pubmed" id="12594313" target="_blank">12594313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22883417">
<a name="22883417"></a>Gross TG, Orjuela MA, Perkins SL, et al. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. <i>Am J Transplant</i>. 2012;12(11):3069-3075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22883417/pubmed" id="22883417" target="_blank">22883417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1676753">
<a name="1676753"></a>Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. <i>J Rheumatol.</i> 1991;18(4):567-574.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/1676753/pubmed" id="1676753" target="_blank">1676753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7488285">
<a name="7488285"></a>Guillevin L, Lhote F, Cohen P, et al. Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteritis nodosa and Churg-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. <i>Arthritis Rheum</i>. 1995;38(11):1638-1645. doi:10.1002/art.1780381116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7488285/pubmed" id="7488285" target="_blank">7488285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18679133">
<a name="18679133"></a>Gupta D, Zachariah A, Roppelt H, Patel AM, Gruber BL. Prophylactic antibiotic usage for <i>Pneumocystis jirovecii</i> pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. <i>J Clin Rheumatol</i>. 2008;14(5):267-272. doi:10.1097/RHU.0b013e31817a7e30<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18679133/pubmed" id="18679133" target="_blank">18679133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556106">
<a name="22556106"></a>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. <i>Arthritis Care Res (Hoboken).</i> 2012;64(6):797-808.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22556106/pubmed" id="22556106" target="_blank">22556106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16894524">
<a name="16894524"></a>Hahn KM, Johnson PH, Gordon N, et al. Treatment of Pregnant Breast Cancer Patients and Outcomes of Children Exposed to Chemotherapy <i>In utero. </i>
<i>Cancer.</i> 2006;107(6):1219-1226.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16894524/pubmed" id="16894524" target="_blank">16894524</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12583625">
<a name="12583625"></a>Hamada K, Nagai S, Kitaichi M, et al. Cyclophosphamide-induced late-onset lung disease. <i>Intern Med</i>. 2003;42(1):82-87. doi:10.2169/internalmedicine.42.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12583625/pubmed" id="12583625" target="_blank">12583625</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22248715">
<a name="22248715"></a>Hamadani M, Kochuparambil ST, Osman S, et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. <i>Biol Blood Marrow Transplant</i>. 2012;18(7):1128-1135. doi:10.1016/j.bbmt.2012.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22248715/pubmed" id="22248715" target="_blank">22248715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30271446">
<a name="30271446"></a>Hamzeh M, Hosseinimehr SJ, Khalatbary AR, Mohammadi HR, Dashti A, Amiri FT. Atorvastatin mitigates cyclophosphamide-induced hepatotoxicity via suppression of oxidative stress and apoptosis in rat model. <i>Res Pharm Sci</i>. 2018;13(5):440-449. doi:10.4103/1735-5362.236837<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30271446/pubmed" id="30271446" target="_blank">30271446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22128076">
<a name="22128076"></a>Harper L, Morgan MD, Walsh M, et al. Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. <i>Ann Rheum Dis.</i> 2012;71(6):955-960.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22128076/pubmed" id="22128076" target="_blank">22128076</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11918757">
<a name="11918757"></a>Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. <i>Kidney Int</i>. 2002;61(4):1495-1501. doi:10.1046/j.1523-1755.2002.00279.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11918757/pubmed" id="11918757" target="_blank">11918757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32658626">
<a name="32658626"></a>Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO guideline update. <i>J Clin Oncol</i>. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32658626/pubmed" id="32658626" target="_blank">32658626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16123223">
<a name="16123223"></a>Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i>. 2005;106(12):3725-3732. doi:10.1182/blood-2005-01-0016<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16123223/pubmed" id="16123223" target="_blank">16123223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21967976">
<a name="21967976"></a>Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2011;118(23):6043-6049.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21967976/pubmed" id="21967976" target="_blank">21967976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23512246">
<a name="23512246"></a>Hopfinger G, Busch R, Pflug N, et al. Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. <i>Cancer</i>. 2013;119(12):2258-2267. doi:10.1002/cncr.27972<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23512246/pubmed" id="23512246" target="_blank">23512246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30522922">
<a name="30522922"></a>Horwitz S, O'Connor OA, Pro B, et al; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet</i>. 2019;393(10168):229-240. doi:10.1016/S0140-6736(18)32984-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30522922/pubmed" id="30522922" target="_blank">30522922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12209517">
<a name="12209517"></a>Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. <i>Arthritis Rheum</i>. 2002;46(8):2121-2131. doi:10.1002/art.10461<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12209517/pubmed" id="12209517" target="_blank">12209517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17133610">
<a name="17133610"></a>Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. <i>Arthritis Rheum</i>. 2006;54(12):3962-3970. doi: 10.1002/art.22204.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17133610/pubmed" id="17133610" target="_blank">17133610</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18780317">
<a name="18780317"></a>Huang H, Abraham J, Hung E, et al. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. <i>Cancer</i>. 2008;113(8):2020-2028.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18780317/pubmed" id="18780317" target="_blank">18780317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27267459">
<a name="27267459"></a>Huart A, Josse AG, Chauveau D, et al; French Society of Hemapheresis. Outcomes of patients with Goodpasture syndrome: a nationwide cohort-based study from the French Society of Hemapheresis. <i>J Autoimmun</i>. 2016;73:24-29. doi:10.1016/j.jaut.2016.05.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27267459/pubmed" id="27267459" target="_blank">27267459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29863974">
<a name="29863974"></a>Huguet F, Chevret S, Leguay T, et al; Group of Research on Adult ALL (GRAALL). Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial.<i> J Clin Oncol</i>. 2018;36(24):2514-2523. doi:10.1200/JCO.2017.76.8192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29863974/pubmed" id="29863974" target="_blank">29863974</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19124805">
<a name="19124805"></a>Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. <i>J Clin Oncol</i>. 2009;27(6):911-918. doi:10.1200/JCO.2008.18.6916<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19124805/pubmed" id="19124805" target="_blank">19124805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30552952">
<a name="30552952"></a>Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. <i>Life Sci</i>. 2019;218:112-131. doi:10.1016/j.lfs.2018.12.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30552952/pubmed" id="30552952" target="_blank">30552952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27079957">
<a name="27079957"></a>Ishida S, Doki N, Shingai N, et al. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). <i>Ann Hematol</i>. 2016;95(7):1145-1150. doi:10.1007/s00277-016-2654-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27079957/pubmed" id="27079957" target="_blank">27079957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26805758">
<a name="26805758"></a>Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. <i>Am J Hematol</i>. 2016;91(2):220-226. doi:10.1002/ajh.24242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26805758/pubmed" id="26805758" target="_blank">26805758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11024423">
<a name="11024423"></a>Jabs DA, Rosenbaum JT, Foster CS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. <i>Am J Ophthalmol</i>. 2000;130(4):492-513.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11024423/pubmed" id="11024423" target="_blank">11024423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jacobson.2020">
<a name="Jacobson.2020"></a>Jacobson C, Chavez JC, Sehgal AR, et al. Primary analysis of zuma-5: a phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL). <i>Blood.</i> 2020;136(suppl 1):40-41. [Abstract 623 from ASH 2020 annual meeting]. doi:10.1182/blood-2020-136834</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jaime-Perez.1">
<a name="Jaime-Perez.1"></a>Jaime-Perez JC, Gonzalez-Llano O, Cantu-Rodriguez OG, et al. Long-term remission and bone marrow findings in children with severe aplastic anemia immunosuppressed with high doses of cyclophosphamide. <i>Journal of Bone Marrow Research</i>. 2013;1(1):1-4.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20118214">
<a name="20118214"></a>Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients. <i>Ann Oncol.</i> 2010;21(7):1395-1403. doi:10.1093/annonc/mdp598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20118214/pubmed" id="20118214" target="_blank">20118214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12840090">
<a name="12840090"></a>Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. <i>N Engl J Med.</i> 2003;349(1):36-44.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12840090/pubmed" id="12840090" target="_blank">12840090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17494881">
<a name="17494881"></a>Jha V, Ganguli A, Saha TK, et al. A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy. <i>J Am Soc Nephrol</i>. 2007;18(6):1899-1904. doi:10.1681/ASN.2007020166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17494881/pubmed" id="17494881" target="_blank">17494881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2718490">
<a name="2718490"></a>Jones JB, Purdy CY, Bailey RT Jr. Cyclophosphamide anaphylaxis. <i>DICP</i>. 1989;23(1):88-89. doi:10.1177/106002808902300125<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2718490/pubmed" id="2718490" target="_blank">2718490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19204201">
<a name="19204201"></a>Jones S, Holmes FA, O'Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. <i>J Clin Oncol</i>. 2009;27(8):1177-1183. doi:10.1200/JCO.2008.18.4028<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19204201/pubmed" id="19204201" target="_blank">19204201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6468474">
<a name="6468474"></a>Juma FD. Effect of liver failure on the pharmacokinetics of cyclophosphamide. <i>Eur J Clin Pharmacol</i>. 1984;26(5):591-593. doi:10.1007/BF00543491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/6468474/pubmed" id="6468474" target="_blank">6468474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25267759">
<a name="25267759"></a>Kanakry CG, O'Donnell PV, Furlong T, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. <i>J Clin Oncol</i>. 2014a;32(31):3497-505. doi:10.1200/JCO.2013.54.0625<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25267759/pubmed" id="25267759" target="_blank">25267759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25316679">
<a name="25316679"></a>Kanakry CG, Tsai HL, Bolaños-Meade J, et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. <i>Blood</i>. 2014b;124(25):3817-3827. doi:10.1182/blood-2014-07-587477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25316679/pubmed" id="25316679" target="_blank">25316679</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653870">
<a name="10653870"></a>Kantarjian HM, O'Brien S, Smith TL, et al. Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. <i>J Clin Oncol.</i> 2000;18(3): 547-561.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10653870/pubmed" id="10653870" target="_blank">10653870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaplan.1">
<a name="Kaplan.1"></a>Kaplan AA, Appel GB, Pusey CD. Anti-GBM (Goodpasture) disease: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23871408">
<a name="23871408"></a>KDIGO. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. <i>Am J Kidney Dis</i>. 2013;62(3):403-441.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23871408/pubmed" id="23871408" target="_blank">23871408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21079154">
<a name="21079154"></a>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP Chemotherapy is a Highly Effective Regimen in Children and Adolescents With High-Risk Hodgkin lymphoma: A Report from the Children's Oncology Group. <i>Blood.</i> 2011;117(9):2596-2603.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21079154/pubmed" id="21079154" target="_blank">21079154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20103616">
<a name="20103616"></a>Kennedy R, Groepper D, Tagen M, et al. Stability of Cyclophosphamide in Extemporaneous Oral Suspensions. <i>Ann Pharmacother</i>. 2010, 44(2):295-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20103616/pubmed" id="20103616" target="_blank">20103616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22107129">
<a name="22107129"></a>Khan ML, Reeder CB, Kumar SK, et al. A Comparison of Lenalidomide/Dexamethasone versus Cyclophosphamide/Lenalidomide/Dexamethasone versus Cyclophosphamide/Bortezomib/Dexamethasone in Newly Diagnosed Multiple Myeloma. <i>Br J Haematol.</i> 2012;156(3):326-333.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22107129/pubmed" id="22107129" target="_blank">22107129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18411419">
<a name="18411419"></a>Khouri IF, McLaughlin P, Saliba RM, et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. <i>Blood</i>. 2008;111(12):5530-5536. doi:10.1182/blood-2008-01-136242<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18411419/pubmed" id="18411419" target="_blank">18411419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2012">
<a name="KDIGO.2012"></a>Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guideline for glomerulonephritis. <i>Kidney Int Suppl</i>. 2012;2(2):139-274. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN-Guideline-English.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-King.1">
<a name="King.1"></a>King TE Jr. Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7859226">
<a name="7859226"></a>Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. <i>Cancer Treat Rev</i>. 1995;21(1):33-64. doi:10.1016/0305-7372(95)90010-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7859226/pubmed" id="7859226" target="_blank">7859226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15738299">
<a name="15738299"></a>Kondoh Y, Taniguchi H, Yokoi T, et al. Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. <i>Eur Respir J</i>. 2005;25(3):528-533. doi:10.1183/09031936.05.00071004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15738299/pubmed" id="15738299" target="_blank">15738299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27941129">
<a name="27941129"></a>Kowal-Bielecka O, Fransen J, Avouac J, et al; EUSTAR Coauthors. Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Ann Rheum Dis.</i> 2017;76(8):1327-1339. doi:10.1136/annrheumdis-2016-209909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27941129/pubmed" id="27941129" target="_blank">27941129</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30942181">
<a name="30942181"></a>Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. <i>Lancet Oncol</i>. 2019;20(4):e200-e207. doi:10.1016/S1470-2045(19)30145-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30942181/pubmed" id="30942181" target="_blank">30942181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22541686">
<a name="22541686"></a>Krmar RT, Kagebrand M, Hansson MEA, et al. Renal-limited vasculitis in children: a single-center retrospective long-term follow-up analysis. <i>Clinical Nephrology</i>. 2013;80:388-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22541686/pubmed" id="22541686" target="_blank">22541686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22422823">
<a name="22422823"></a>Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. <i>Blood</i>. 2012a;119(19):4375-4382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22422823/pubmed" id="22422823" target="_blank">22422823</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22504925">
<a name="22504925"></a>Kumar SK, Hayman SR, Buadi FK, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. <i>Blood</i>. 2012b;119(21):4860-4867. doi:10.1182/blood-2012-01-407791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22504925/pubmed" id="22504925" target="_blank">22504925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20564411">
<a name="20564411"></a>Kushner BH, Kramer K, Modak S, Qin LX, Cheung NK. Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. <i>Cancer</i>. 2010;116(12):3054-3060.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20564411/pubmed" id="20564411" target="_blank">20564411</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20934323">
<a name="20934323"></a>Kushner BH, Kramer K, Modak S, Yataghene K, Cheung NK. High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. <i>Eur J Cancer</i>. 2011;47(1):84-89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20934323/pubmed" id="20934323" target="_blank">20934323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7527454">
<a name="7527454"></a>Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly Effective Induction Therapy for Stage 4 Neuroblastoma in Children Over 1 Year of Age. <i>J Clin Oncol. </i>1994;12(12):2607-2613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7527454/pubmed" id="7527454" target="_blank">7527454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622067">
<a name="8622067"></a>Kushner BH, LaQuaglia MP, Wollner N, et al. Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. <i>J Clin Oncol</i>. 1996;14(5):1526-1531.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8622067/pubmed" id="8622067" target="_blank">8622067</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15160953">
<a name="15160953"></a>Lacasce A, Howard O, Fisher D, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. <i>Leuk Lymphoma</i>. 2004;45(4):761-767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15160953/pubmed" id="15160953" target="_blank">15160953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8639922">
<a name="8639922"></a>Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. <i>Blood</i>. 1996;87(7):3000-3006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8639922/pubmed" id="8639922" target="_blank">8639922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7718875">
<a name="7718875"></a>Larson RA, Dodge RK, Burns CP, et al. A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811. <i>Blood.</i> 1995;85(8):2025-2037.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7718875/pubmed" id="7718875" target="_blank">7718875</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27432877">
<a name="27432877"></a>Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i>. 2016;128(10):1321-1328. doi:10.1182/blood-2016-04-711234<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27432877/pubmed" id="27432877" target="_blank">27432877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12860952">
<a name="12860952"></a>Lee CK, Barlogie B, Munshi N, et al. DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. <i>J Clin Oncol</i>. 2003;21(14):2732-2739. doi:10.1200/JCO.2003.01.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12860952/pubmed" id="12860952" target="_blank">12860952</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34943985">
<a name="34943985"></a>Lee S, Lee J, Khimji C, et al. Repeated low-dose acrolein triggers irreversible lamina propria edema in urinary bladder, transient voiding behavior and widening of eyes to mechanical stimuli. <i>Cells</i>. 2021;10(12):3477. doi:10.3390/cells10123477<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34943985/pubmed" id="34943985" target="_blank">34943985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10657833">
<a name="10657833"></a>Lehman TJ, Onel K. Intermittent Intravenous Cyclophosphamide Arrests Progression of the Renal Chronicity Index in Childhood Systemic Lupus Erythematosus. <i>J Pediatr.</i> 2000;136(2):243-247.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10657833/pubmed" id="10657833" target="_blank">10657833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9704715">
<a name="9704715"></a>Levine MN, Bramwell VH, Pritchard KI, et al. Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer. National Cancer Institute of Canada Clinical Trials Group. <i>J Clin Oncol. </i>1998;16(8):2651-2658.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9704715/pubmed" id="9704715" target="_blank">9704715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11388816">
<a name="11388816"></a>Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. <i>Ann Intern Med</i>. 2001;134(11):1033-1042. doi:10.7326/0003-4819-134-11-200106050-00009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11388816/pubmed" id="11388816" target="_blank">11388816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26628463">
<a name="26628463"></a>Lishner M, Avivi I, Apperley JF, et al. Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. <i>J Clin Oncol</i>. 2016;34(5):501-508. doi:10.1200/JCO.2015.62.4445<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26628463/pubmed" id="26628463" target="_blank">26628463</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27063975">
<a name="27063975"></a>Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease: a systematic literature review. <i>Lancet Haematol</i>. 2016;3(4):e163-e175. doi:10.1016/S2352-3026(16)00006-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27063975/pubmed" id="27063975" target="_blank">27063975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15353481">
<a name="15353481"></a>Locatelli F, Nöllke P, Zecca M, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial. <i>Blood</i>. 2005;105(1):410-419.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15353481/pubmed" id="15353481" target="_blank">15353481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30518502">
<a name="30518502"></a>Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. <i>Lancet Oncol</i>. 2019;20(1):31-42. doi:10.1016/S1470-2045(18)30864-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30518502/pubmed" id="30518502" target="_blank">30518502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34891224">
<a name="34891224"></a>Locke FL, Miklos DB, Jacobson CA, et al; All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.<i> N Engl J Med</i>. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34891224/pubmed" id="34891224" target="_blank">34891224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201378">
<a name="8201378"></a>Loehrer PJ Sr, Kim K, Aisner SC, et al; The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. <i>J Clin Oncol</i>. 1994;12(6):1164-1168. doi:10.1200/JCO.1994.12.6.1164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8201378/pubmed" id="8201378" target="_blank">8201378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247818">
<a name="26247818"></a>Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. <i>JAMA Oncol</i>. 2015;1(8):1145-1153. doi: 10.1001/jamaoncol.2015.2413<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26247818/pubmed" id="26247818" target="_blank">26247818</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16342247">
<a name="16342247"></a>Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. <i>Cancer</i>. 2006;106(2):237-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16342247/pubmed" id="16342247" target="_blank">16342247</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26168069">
<a name="26168069"></a>Lunde LE, Dasaraju S, Cao Q, et al. Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. <i>Bone Marrow Transplant</i>. 2015;50(11):1432-1437. doi:10.1038/bmt.2015.162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26168069/pubmed" id="26168069" target="_blank">26168069</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17086804">
<a name="17086804"></a>Lurain JR, Singh DK, Schink JC. Primary treatment of metastatic high-risk gestational trophoblastic neoplasia with EMA-CO chemotherapy. <i>J Reprod Med</i>. 2006;51(10):767-772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17086804/pubmed" id="17086804" target="_blank">17086804</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20124511">
<a name="20124511"></a>Luznik L, Bolaños-Meade J, Zahurak M, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. <i>Blood</i>. 2010;115(16):3224-3230. doi:10.1182/blood-2009-11-251595<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20124511/pubmed" id="20124511" target="_blank">20124511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8622041">
<a name="8622041"></a>Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. <i>J Clin Oncol. </i>1996;14(3):925-934.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8622041/pubmed" id="8622041" target="_blank">8622041</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34108676">
<a name="34108676"></a>Mac S, Ngo D, Yang D, et al. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplant</i>. 2021;56(10):2464-2470. doi:10.1038/s41409-021-01364-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34108676/pubmed" id="34108676" target="_blank">34108676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8941578">
<a name="8941578"></a>Mak SK, Short CD, Mallick NP. Long-term outcome of adult-onset minimal-change nephropathy. <i>Nephrol Dial Transplant</i>. 1996;11(11):2192-2201. doi:10.1093/oxfordjournals.ndt.a027136<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8941578/pubmed" id="8941578" target="_blank">8941578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20926773">
<a name="20926773"></a>Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. <i>Blood</i>. 2011;117(1):316-322. doi:10.1182/blood-2010-07-294629<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20926773/pubmed" id="20926773" target="_blank">20926773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8970380">
<a name="8970380"></a>Malik SW, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. <i>Am J Respir Crit Care Med.</i> 1996;154(6, pt 1):1851-1856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8970380/pubmed" id="8970380" target="_blank">8970380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17539021">
<a name="17539021"></a>Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. <i>Pediatr Blood Cancer</i>. 2008;50(2):236-241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17539021/pubmed" id="17539021" target="_blank">17539021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33275674">
<a name="33275674"></a>Malpica L, Moll S. Practical approach to monitoring and prevention of infectious complications associated with systemic corticosteroids, antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant hematologic diseases. <i>Hematology Am Soc Hematol Educ Program</i>. 2020;2020(1):319-327. doi:10.1182/hematology.2020000116<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33275674/pubmed" id="33275674" target="_blank">33275674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28976863">
<a name="28976863"></a>Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. <i>N Engl J Med</i>. 2017;377(14):1331-1344. doi:10.1056/NEJMoa1614598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28976863/pubmed" id="28976863" target="_blank">28976863</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15494430">
<a name="15494430"></a>Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i>. 2005;105(4):1417-1423. doi:10.1182/blood-2004-08-3175<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15494430/pubmed" id="15494430" target="_blank">15494430</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21740984">
<a name="21740984"></a>Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. <i>Autoimmun Rev</i>. 2011;11(1):6-13. doi:10.1016/j.autrev.2011.06.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21740984/pubmed" id="21740984" target="_blank">21740984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23489519">
<a name="23489519"></a>Mårtensson T1, Priftakis P, Casswall T, et al. Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning. <i>Pediatr Transplant</i>. 2013;17(3):285-293.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23489519/pubmed" id="23489519" target="_blank">23489519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21738257">
<a name="21738257"></a>Martínez-Gabarrón M, Enríquez R, Sirvent AE, García-Sepulcre M, Millán I, Amorós F. Hepatotoxicity following cyclophosphamide treatment in a patient with MPO-ANCA vasculitis. <i>Nefrologia</i>. 2011;31(4):496-498. doi:10.3265/Nefrologia.pre2011.May.10917<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21738257/pubmed" id="21738257" target="_blank">21738257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9440745">
<a name="9440745"></a>Mason WP, Grovas A, Halpern S, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. <i>J Clin Oncol</i>. 1998;16(1):210-221.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9440745/pubmed" id="9440745" target="_blank">9440745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29385370">
<a name="29385370"></a>Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. <i>N Engl J Med</i>. 2018;378(5):439-448. doi:10.1056/NEJMoa1709866<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29385370/pubmed" id="29385370" target="_blank">29385370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28356445">
<a name="28356445"></a>McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. <i>Circulation</i>. 2017;135(17):e927-e999.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28356445/pubmed" id="28356445" target="_blank">28356445</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McCune.1">
<a name="McCune.1"></a>McCune WJ, Clowse MB. General principles of the use of cyclophosphamide in rheumatic diseases. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12406916">
<a name="12406916"></a>McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. <i>Blood</i>. 2003;101(5):2043-2048. doi:10.1182/blood-2002-06-1860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12406916/pubmed" id="12406916" target="_blank">12406916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Means.1">
<a name="Means.1"></a>Means RT Jr. Acquired pure red cell aplasia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28134084">
<a name="28134084"></a>Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L. <i>Pneumocystis jiroveci</i> pneumonia in rheumatic disease: a 20-year single-centre experience. <i>Clin Exp Rheumatol</i>. 2017;35(4):671-673.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28134084/pubmed" id="28134084" target="_blank">28134084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.1">
<a name="Merkel.1"></a>Merkel PA. Treatment and prognosis of polyarteritis nodosa. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merkel.2">
<a name="Merkel.2"></a>Merkel PA, Kaplan AA, Falk RJ. Granulomatosis with polyangiitis and microscopic polyangiitis: induction and maintenance therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 6, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyrier.1">
<a name="Meyrier.1"></a>Meyrier A, Radhakrishnan J. Minimal change disease: treatment in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 20, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22331188">
<a name="22331188"></a>Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. <i>Blood</i>. 2012;119(19):4391-4394. doi:10.1182/blood-2011-11-390930<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22331188/pubmed" id="22331188" target="_blank">22331188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31598736">
<a name="31598736"></a>Mills KA, Chess-Williams R, McDermott C. Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde's contribution to urothelial dysfunction in vitro. <i>Arch Toxicol</i>. 2019;93(11):3291-3303. doi:10.1007/s00204-019-02589-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/31598736/pubmed" id="31598736" target="_blank">31598736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22162255">
<a name="22162255"></a>Mina R, Scheven E, Ardoin SP, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(3):375-383.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22162255/pubmed" id="22162255" target="_blank">22162255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31686598">
<a name="31686598"></a>Ming Z, Yongqiang Z, Zijin Z, Yan X, Di C, Xiaoxin T. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a <i>CYP2B6*7</i> variant. <i>Pharmacogenomics</i>. 2019;20(16):1119-1124. doi:10.2217/pgs-2019-0093<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/31686598/pubmed" id="31686598" target="_blank">31686598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moccia.1">
<a name="Moccia.1"></a>Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. <i>Blood.</i> 2009;114(22).</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9588734">
<a name="9588734"></a>Mok CC, Lau CS, Wong RW. Risk Factors for Ovarian Failure in Patients With Systemic Lupus Erythematosus Receiving Cyclophosphamide Therapy. <i>Arthritis Rheum.</i> 1998;41(5):831-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9588734/pubmed" id="9588734" target="_blank">9588734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12892257">
<a name="12892257"></a>Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. <i>Scand J Rheumatol</i>. 2003;32(3):181-183. doi:10.1080/03009740310002542<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12892257/pubmed" id="12892257" target="_blank">12892257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2025981">
<a name="2025981"></a>Moore MJ. Clinical pharmacokinetics of cyclophosphamide. <i>Clin Pharmacokinet</i>. 1991;20(3):194-208. doi:10.2165/00003088-199120030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2025981/pubmed" id="2025981" target="_blank">2025981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21276754">
<a name="21276754"></a>Morgan C, Tillett T, Braybrooke J, Ajithkumar T. Management of Uncommon Chemotherapy-Induced Emergencies. <i>Lancet Oncol.</i> 2011;12(8):806-814. doi:10.1016/S1470-2045(10)70208-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21276754/pubmed" id="21276754" target="_blank">21276754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28850718">
<a name="28850718"></a>Moshe Y, Bentur OS, Lishner M, Avivi I. The management of hodgkin lymphomas in pregnancies. <i>Eur J Haematol</i>. 2017;99(5):385-391. doi:10.1111/ejh.12956<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28850718/pubmed" id="28850718" target="_blank">28850718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12091370">
<a name="12091370"></a>Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. <i>Blood</i>. 2002;100(2):704-706. doi:10.1182/blood-2002-01-0087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/12091370/pubmed" id="12091370" target="_blank">12091370</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413444">
<a name="18413444"></a>Mukhtyar C, Guillevin L, Cid MC, et al; European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Ann Rheum Dis</i>. 2009;68(3):310-317. doi:10.1136/ard.2008.088096<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18413444/pubmed" id="18413444" target="_blank">18413444</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33626253">
<a name="33626253"></a>Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. <i>N Engl J Med</i>. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/33626253/pubmed" id="33626253" target="_blank">33626253</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29226797">
<a name="29226797"></a>Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N Engl J Med</i>. 2017;377(26):2531-2544. doi:10.1056/NEJMoa1707447<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29226797/pubmed" id="29226797" target="_blank">29226797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nemecek.1">
<a name="Nemecek.1"></a>Nemecek BD, Hammond DA, eds. <i>Demystifying Drug Dosing in Renal Dysfunction</i>. American Society of Health-System Pharmacists; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29620997">
<a name="29620997"></a>Oktay K, Harvey BE, Partridge AH, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. <i>J Clin Oncol</i>. 2018;36(19):1994-2001. doi:10.1200/JCO.2018.78.1914<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29620997/pubmed" id="29620997" target="_blank">29620997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ostermann-Kraljevic.1">
<a name="Ostermann-Kraljevic.1"></a>Ostermann-Kraljevic S, Berger M, Voeffray M, Pannatier A. Stability and compatibility studies of antineoplastic agents in glass and polyethylene containers. <i>EHP</i>. 1999;5(4):162-168.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27400984">
<a name="27400984"></a>Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27400984/pubmed" id="27400984" target="_blank">27400984</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25987656">
<a name="25987656"></a>Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. <i>Blood</i>. 2015;126(5):612-615. doi:10.1182/blood-2015-01-620302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25987656/pubmed" id="25987656" target="_blank">25987656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010014">
<a name="22010014"></a>Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. <i>J Clin Oncol</i>. 2011;29(33):4351-4357.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22010014/pubmed" id="22010014" target="_blank">22010014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21131038">
<a name="21131038"></a>Parker C, Waters R, Leighton C, et al. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. <i>Lancet</i>. 2010;376(9757):2009-2017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21131038/pubmed" id="21131038" target="_blank">21131038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2195554">
<a name="2195554"></a>Patel JM. Metabolism and pulmonary toxicity of cyclophosphamide. <i>Pharmacol Ther</i>. 1990;47(1):137-146. doi:10.1016/0163-7258(90)90049-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2195554/pubmed" id="2195554" target="_blank">2195554</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17132719">
<a name="17132719"></a>Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. <i>Blood</i>. 2007;109(7):2773-2780.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17132719/pubmed" id="17132719" target="_blank">17132719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30143960">
<a name="30143960"></a>Pavlov-Dolijanovic S, Vujasinovic Stupar N, Zugic V, et al. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients. <i>Clin Rheumatol</i>. 2018;37(11):3043-3050. doi:10.1007/s10067-018-4266-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30143960/pubmed" id="30143960" target="_blank">30143960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30729654">
<a name="30729654"></a>Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: a clinical practice guideline. <i>Pediatr Blood Cancer</i>. 2019;66(5):e27646. doi:10.1002/pbc.27646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30729654/pubmed" id="30729654" target="_blank">30729654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi167.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29209521">
<a name="29209521"></a>Pedrazzoli P, Silvestris N, Santoro A, et al. Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). <i>ESMO Open</i>. 2017;2(3):e000167. doi:10.1136/esmoopen-2017-000167<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/29209521/pubmed" id="29209521" target="_blank">29209521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14982884">
<a name="14982884"></a>Pfreundschuh M, Trümper L, Kloess M, et al; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. <i>Blood</i>. 2004;104(3):626-633. doi:10.1182/blood-2003-06-2094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/14982884/pubmed" id="14982884" target="_blank">14982884</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18302711">
<a name="18302711"></a>Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. <i>Br J Haematol</i>. 2008;140(6):625-634. doi:10.1111/j.1365-2141.2007.06921.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18302711/pubmed" id="18302711" target="_blank">18302711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8159300">
<a name="8159300"></a>Ponticelli C, Edefonti A, Ghio L, et al. Cyclosporin versus cyclophosphamide for patients with steroid-dependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. <i>Nephrol Dial Transplant</i>. 1993;8(12):1326-1332.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8159300/pubmed" id="8159300" target="_blank">8159300</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Procytox.1">
<a name="Procytox.1"></a>Procytox (cyclophosphamide) [product monograph]. Mississauga, Ontario, Canada: Baxter; September 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8814058">
<a name="8814058"></a>Pryor BD, Bologna SG, Kahl LE. Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. <i>Arthritis Rheum</i>. 1996;39(9):1475-1482. doi:10.1002/art.1780390906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8814058/pubmed" id="8814058" target="_blank">8814058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19969366">
<a name="19969366"></a>Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. <i>Ophthalmology</i>. 2010;117(2):356-365.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19969366/pubmed" id="19969366" target="_blank">19969366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20466853">
<a name="20466853"></a>Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <i>Blood</i>. 2010;116(12):2070-2077. doi:10.1182/blood-2009-12-261586<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20466853/pubmed" id="20466853" target="_blank">20466853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1919637">
<a name="1919637"></a>Reece DE, Barnett MJ, Connors JM, et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. <i>J Clin Oncol.</i> 1991;9(10):1871-1879.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/1919637/pubmed" id="1919637" target="_blank">1919637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11723769">
<a name="11723769"></a>Regan MJ, Hellmann DB, Stone JH. Treatment of Wegener's granulomatosis. <i>Rheum Dis Clin North Am</i>. 2001;27(4):863-886, viii. doi:10.1016/s0889-857x(05)70240-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11723769/pubmed" id="11723769" target="_blank">11723769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10817555">
<a name="10817555"></a>Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. <i>Arthritis Rheum</i>. 2000;43(5):1021-1032. doi:10.1002/1529-0131(200005)43:5&lt;1021::AID-ANR10&gt;3.0.CO;2-J<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10817555/pubmed" id="10817555" target="_blank">10817555</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8164040">
<a name="8164040"></a>Reiter A, Schrappe M, Tiemann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. <i>J Clin Oncol</i>. 1994;12(5):899-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8164040/pubmed" id="8164040" target="_blank">8164040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24428673">
<a name="24428673"></a>Rizzieri DA, Johnson JL, Byrd JC, et al; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. <i>Br J Haematol</i>. 2014;165(1):102-111. doi:10.1111/bjh.12736<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24428673/pubmed" id="24428673" target="_blank">24428673</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20194844">
<a name="20194844"></a>Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia. <i>J Clin Oncol.</i> 2010;28(10):1756-1765.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20194844/pubmed" id="20194844" target="_blank">20194844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24123865">
<a name="24123865"></a>Robison NJ, Campigotto F, Chi SN, et al. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. <i>Pediatr Blood Cancer</i>. 2014;61(4):636-642.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24123865/pubmed" id="24123865" target="_blank">24123865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11972091">
<a name="11972091"></a>Rodríguez-Galindo C, Daw NC, Kaste SC, et al. Treatment of refractory osteosarcoma with fractionated cyclophosphamide and etoposide. <i>J Pediatr Hematol Oncol</i>. 2002;24(4):250-255. doi:10.1097/00043426-200205000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11972091/pubmed" id="11972091" target="_blank">11972091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al; participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10992015">
<a name="10992015"></a>Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. <i>Radiographics</i>. 2000;20(5):1245-1259. doi:10.1148/radiographics.20.5.g00se081245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10992015/pubmed" id="10992015" target="_blank">10992015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24847759">
<a name="24847759"></a>Roumier M, Loustau V, Guillaud C, et al. Characteristics and outcome of warm autoimmune hemolytic anemia in adults: New insights based on a single-center experience with 60 patients. <i>Am J Hematol</i>. 2014;89(9):E150-E155. doi: 10.1002/ajh.23767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24847759/pubmed" id="24847759" target="_blank">24847759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30665569">
<a name="30665569"></a>Rovin BH, Caster DJ, Cattran DC, et al; Conference Participants. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney Int</i>. 2019;95(2):281-295. doi:10.1016/j.kint.2018.11.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30665569/pubmed" id="30665569" target="_blank">30665569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16105981">
<a name="16105981"></a>Rowe JM, Buck G, Burnett AK, et al; MRC/NCRI Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <i>Blood</i>. 2005;106(12):3760-3767. doi:10.1182/blood-2005-04-1623<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16105981/pubmed" id="16105981" target="_blank">16105981</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21172879">
<a name="21172879"></a>Rubie H, De Bernardi B, Gerrard M, et al. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1. <i>J Clin Oncol</i>. 2011;29(4):449-455.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21172879/pubmed" id="21172879" target="_blank">21172879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23603381">
<a name="23603381"></a>Saba, Khan S, Parvez S, et al. Ellagic acid attenuates bleomycin and cyclophosphamide-induced pulmonary toxicity in Wistar rats. <i>Food Chem Toxicol</i>. 2013;58:210-219. doi:10.1016/j.fct.2013.03.046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23603381/pubmed" id="23603381" target="_blank">23603381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26696797">
<a name="26696797"></a>Salama A. Treatment options for primary autoimmune hemolytic anemia: a short comprehensive review. <i>Transfus Med Hemother</i>. 2015;42(5):294-301. doi:10.1159/000438731<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26696797/pubmed" id="26696797" target="_blank">26696797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32090480">
<a name="32090480"></a>Sammaritano LR, Bermas BL, Chakravarty EE, et al. 2020 American College of Rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. <i>Arthritis Rheumatol</i>. 2020;72(4):529‐556. doi:10.1002/art.41191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32090480/pubmed" id="32090480" target="_blank">32090480</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16199317">
<a name="16199317"></a>Sampath S, Schultheiss TE, Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. <i>Int J Radiat Oncol Biol Phys</i>. 2005;63(3):876-884. doi:10.1016/j.ijrobp.2005.02.032<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16199317/pubmed" id="16199317" target="_blank">16199317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26475490">
<a name="26475490"></a>Sasak G, Zemheri E, Ozkok A. Toxic epidermal necrolysis due to cyclophosphamide. <i>Clin Exp Nephrol</i>. 2016;20(4):660-661. doi:10.1007/s10157-015-1181-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26475490/pubmed" id="26475490" target="_blank">26475490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18510682">
<a name="18510682"></a>Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. <i>Br J Haematol</i>. 2008;142(4):505-514. doi:10.1111/j.1365-2141.2008.07216.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18510682/pubmed" id="18510682" target="_blank">18510682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20660290">
<a name="20660290"></a>Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. <i>Blood</i>. 2010;116(18):3418-3425. doi:10.1182/blood-2010-02-270785<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20660290/pubmed" id="20660290" target="_blank">20660290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501490">
<a name="30501490"></a>Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2019;380(1):45-56. doi:10.1056/NEJMoa1804980<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30501490/pubmed" id="30501490" target="_blank">30501490</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19584400">
<a name="19584400"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19584400/pubmed" id="19584400" target="_blank">19584400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11485142">
<a name="11485142"></a>Segura A, Yuste A, Cercos A, et al. Pulmonary fibrosis induced by cyclophosphamide. <i>Ann Pharmacother</i>. 2001;35(7-8):894-897. doi:10.1345/aph.10297<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11485142/pubmed" id="11485142" target="_blank">11485142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11389005">
<a name="11389005"></a>Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. <i>Blood</i>. 2001;97(12):3699-3706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11389005/pubmed" id="11389005" target="_blank">11389005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19707509">
<a name="19707509"></a>Seo HY, Kim EB, Kim JW, Shin BK, Kim SJ, Kim BS. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. <i>Cancer Res Treat</i>. 2009;41(2):104-107. doi:10.4143/crt.2009.41.2.104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/19707509/pubmed" id="19707509" target="_blank">19707509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28232597">
<a name="28232597"></a>Shachar SS, Gallagher K, McGuire K, et al. Multidisciplinary management of breast cancer during pregnancy. <i>Oncologist</i>. 2017;22(3):324-334. doi:10.1634/theoncologist.2016-0208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28232597/pubmed" id="28232597" target="_blank">28232597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34097852">
<a name="34097852"></a>Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. <i>Lancet.</i> 2021;398(10299):491-502. doi:10.1016/S0140-6736(21)01222-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34097852/pubmed" id="34097852" target="_blank">34097852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3060893">
<a name="3060893"></a>Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. <i>Q J Med</i>. 1988;67(252):309-317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/3060893/pubmed" id="3060893" target="_blank">3060893</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553975">
<a name="20553975"></a>Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. <i>Autoimmun Rev</i>. 2010;9(10):674-683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20553975/pubmed" id="20553975" target="_blank">20553975</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2988740">
<a name="2988740"></a>Slayton RE, Park RC, Silverberg SG, et al. Vincristine, Dactinomycin, and Cyclophosphamide in the Treatment of Malignant Germ Cell Tumors of the Ovary. A Gynecologic Oncology Group Study (A Final Report). <i>Cancer</i>. 1985;56(2):243-248.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/2988740/pubmed" id="2988740" target="_blank">2988740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18413641">
<a name="18413641"></a>Soussain C, Hoang-Xuan K, Taillandier L, et al; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. <i>J Clin Oncol</i>. 2008;26(15):2512-2518. doi:10.1200/JCO.2007.13.5533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18413641/pubmed" id="18413641" target="_blank">18413641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11157026">
<a name="11157026"></a>Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. <i>J Clin Oncol</i>. 2001;19(3):742-749. doi:10.1200/JCO.2001.19.3.742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11157026/pubmed" id="11157026" target="_blank">11157026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8221579">
<a name="8221579"></a>Steinherz PG, Redner A, Steinherz L, Meyers P, Tan C, Heller G. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse. The Memorial Sloan-Kettering-New York-II protocol. <i>Cancer</i>. 1993;72(10):3120-3130.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8221579/pubmed" id="8221579" target="_blank">8221579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3604756">
<a name="3604756"></a>Stentoft J. Progressive pulmonary fibrosis complicating cyclophosphamide therapy. <i>Acta Med Scand</i>. 1987;221(4):403-407. doi:10.1111/j.0954-6820.1987.tb03363.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/3604756/pubmed" id="3604756" target="_blank">3604756</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30658992">
<a name="30658992"></a>Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i>. 2019;133(14):1548-1559. doi:10.1182/blood-2018-10-881961<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30658992/pubmed" id="30658992" target="_blank">30658992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20647199">
<a name="20647199"></a>Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. <i>N Engl J Med.</i> 2010;363(3):221-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/20647199/pubmed" id="20647199" target="_blank">20647199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9160700">
<a name="9160700"></a>Storb R, Leisenring W, Anasetti C, et al. Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin. <i>Blood</i>. 1997;89(10):3890-3891.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9160700/pubmed" id="9160700" target="_blank">9160700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24023976">
<a name="24023976"></a>Subramaniam SR, Cader RA, Mohd R, Yen KW, Ghafor HA. Low-dose cyclophosphamide-induced acute hepatotoxicity. <i>Am J Case Rep</i>. 2013;14:345-349. doi:10.12659/AJCR.889401<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/24023976/pubmed" id="24023976" target="_blank">24023976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10856110">
<a name="10856110"></a>Tai PT, Yu E, Winquist E, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. <i>J Clin Oncol</i>. 2000;18(12):2493-2499. doi:10.1200/JCO.2000.18.12.2493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10856110/pubmed" id="10856110" target="_blank">10856110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8602705">
<a name="8602705"></a>Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. <i>Ann Intern Med</i>. 1996;124(5):477-484. doi:10.7326/0003-4819-124-5-199603010-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/8602705/pubmed" id="8602705" target="_blank">8602705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10830189">
<a name="10830189"></a>Tanaka F, Origuchi T, Migita K, et al. Successful combined therapy of cyclophosphamide and cyclosporine for acute exacerbated interstitial pneumonia associated with dermatomyositis. <i>Intern Med</i>. 2000;39(5):428-430. doi:10.2169/internalmedicine.39.428<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10830189/pubmed" id="10830189" target="_blank">10830189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Targoff.1">
<a name="Targoff.1"></a>Targoff IN. Treatment of recurrent and resistant dermatomyositis and polymyositis in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16790698">
<a name="16790698"></a>Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease.<i> N Engl J Med.</i> 2006;354(25):2655-2666. doi:10.1056/NEJMoa055120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16790698/pubmed" id="16790698" target="_blank">16790698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27469583">
<a name="27469583"></a>Tashkin DP, Roth MD, Clements PJ, et al; Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respir Med</i>. 2016;4(9):708-719. doi:10.1016/S2213-2600(16)30152-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/27469583/pubmed" id="27469583" target="_blank">27469583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21732338">
<a name="21732338"></a>Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. <i>Cancer</i>. 2012;118(2):434-443. doi: 10.1002/cncr.26303.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21732338/pubmed" id="21732338" target="_blank">21732338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28530852">
<a name="28530852"></a>Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. <i>J Clin Oncol</i>. 2017;35(20):2288-2298. doi:10.1200/JCO.2016.71.6902<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/28530852/pubmed" id="28530852" target="_blank">28530852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25435734">
<a name="25435734"></a>Thabet AF, Faisal M. Pulse cyclophosphamide therapy in refractory warm autoimmune hemolytic anemia: a new perspective. <i>Indian J Hematol Blood Transfus</i>. 2014;30(4):313-318. doi:10.1007/s12288-013-0290-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25435734/pubmed" id="25435734" target="_blank">25435734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14551133">
<a name="14551133"></a>Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. <i>Blood</i>. 2004;103(12):4396-4407. doi:10.1182/blood-2003-08-2958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/14551133/pubmed" id="14551133" target="_blank">14551133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16502413">
<a name="16502413"></a>Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580. doi:10.1002/cncr.21776<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16502413/pubmed" id="16502413" target="_blank">16502413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18256325">
<a name="18256325"></a>Thompson JA, Fisher RI, Leblanc M, et al. Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the Southwest Oncology Group (SWOG 9438). <i>Blood.</i> 2008;111(8):4048-4054.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/18256325/pubmed" id="18256325" target="_blank">18256325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11958577">
<a name="11958577"></a>Thong BY, Leong KP, Thumboo J, Koh ET, Tang CY. Cyclophosphamide type I hypersensitivity in systemic lupus erythematosus. <i>Lupus</i>. 2002;11(2):127-129. doi:10.1191/0961203302lu140cr<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11958577/pubmed" id="11958577" target="_blank">11958577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34904799">
<a name="34904799"></a>Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. <i>N Engl J Med</i>. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34904799/pubmed" id="34904799" target="_blank">34904799</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11830608">
<a name="11830608"></a>Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. <i>J Natl Cancer Inst</i>. 2002;94(3):182-192. doi:10.1093/jnci/94.3.182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/11830608/pubmed" id="11830608" target="_blank">11830608</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17968021">
<a name="17968021"></a>Tsukasaki K, Utsunomiya A, Fukuda H, et al; Japan Clinical Oncology Group Study JCOG9801. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. <i>J Clin Oncol</i>. 2007;25(34):5458-5464. doi:10.1200/JCO.2007.11.9958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17968021/pubmed" id="17968021" target="_blank">17968021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3311203">
<a name="3311203"></a>Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. <i>Blood</i>. 1987;70(5):1382-1388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/3311203/pubmed" id="3311203" target="_blank">3311203</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30181172">
<a name="30181172"></a>van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. <i>Blood</i>. 2018;132(20):2115-2124. doi:10.1182/blood-2018-07-862334<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30181172/pubmed" id="30181172" target="_blank">30181172</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varga.1">
<a name="Varga.1"></a>Varga J, Montesi S. Treatment and prognosis of interstitial lung disease in systemic sclerosis (scleroderma). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 19, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22331187">
<a name="22331187"></a>Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. <i>Blood</i>. 2012;119(19):4387-4390. doi:10.1182/blood-2011-10-388462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/22331187/pubmed" id="22331187" target="_blank">22331187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15172775">
<a name="15172775"></a>Verhelst D, Rossert J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. <i>Lancet</i>. 2004;363(9423):1768-1771. doi:10.1016/S0140-6736(04)16302-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/15172775/pubmed" id="15172775" target="_blank">15172775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10080612">
<a name="10080612"></a>von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. <i>J Clin Oncol</i>. 1999;17(2):658-667.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10080612/pubmed" id="10080612" target="_blank">10080612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17699450">
<a name="17699450"></a>Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes. <i>Clin J Am Soc Nephrol</i>. 2007;2(3):445-453. doi:10.2215/CJN.03531006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/17699450/pubmed" id="17699450" target="_blank">17699450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10835091">
<a name="10835091"></a>Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. <i>Pediatrics</i>. 2000;105(6):E78.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/10835091/pubmed" id="10835091" target="_blank">10835091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21298768">
<a name="21298768"></a>Walterhouse DO, Meza JL, Breneman JC, et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2011;57(1):76-83. doi: 10.1002/pbc.22928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/21298768/pubmed" id="21298768" target="_blank">21298768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25267746">
<a name="25267746"></a>Walterhouse DO, Pappo AS, Meza JL, et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol</i>. 2014;32(31):3547-3552.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/25267746/pubmed" id="25267746" target="_blank">25267746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23880225">
<a name="23880225"></a>Wang CC, Weng TI, Lu MY, et al. Hemorrhagic cystitis in children treated with alkylating agent cyclophosphamide: the experience of a medical center in Taiwan. <i>J Formos Med Assoc</i>. 2015;114(8):691-697. doi:10.1016/j.jfma.2013.06.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23880225/pubmed" id="23880225" target="_blank">23880225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7471607">
<a name="7471607"></a>Wang LH, Lee CS, Majeske BL, Marbury TC. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells, and dialysate measurements for cyclophosphamide. <i>Clin Pharmacol Ther</i>. 1981;29(3):365-372. doi:10.1038/clpt.1981.50<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/7471607/pubmed" id="7471607" target="_blank">7471607</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32242358">
<a name="32242358"></a>Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. <i>N Engl J Med</i>. 2020;382(14):1331-1342. doi:10.1056/NEJMoa1914347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/32242358/pubmed" id="32242358" target="_blank">32242358</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9449873">
<a name="9449873"></a>Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants. <i>Lancet</i>. 1998;351(9097):178-181. doi:10.1016/S0140-6736(97)08256-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9449873/pubmed" id="9449873" target="_blank">9449873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16183265">
<a name="16183265"></a>Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of Cyclophosphamide in Patients With Hematologic Malignancies. <i>Eur J Pharm Sci.</i> 2006;27(1):54-61.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16183265/pubmed" id="16183265" target="_blank">16183265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23101661">
<a name="23101661"></a>Xu Y, Wang H, Zhou S, et al. Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma. <i>Leuk Lymphoma</i>. 2013;54(7):1396-1404. doi:10.3109/10428194.2012.743657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/23101661/pubmed" id="23101661" target="_blank">23101661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9163606">
<a name="9163606"></a>Yamada O, Mizoguchi H, Oshimi K. Cyclophosphamide therapy for pure red cell aplasia associated with granular lymphocyte-proliferative disorders. <i>Br J Haematol</i>. 1997;97(2):392-399. doi:10.1046/j.1365-2141.1997.282672.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/9163606/pubmed" id="9163606" target="_blank">9163606</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16754626">
<a name="16754626"></a>Yamasaki Y, Yamada H, Yamasaki M, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. <i>Rheumatology (Oxford)</i>. 2007;46(1):124-130. doi:10.1093/rheumatology/kel112<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/16754626/pubmed" id="16754626" target="_blank">16754626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34592759">
<a name="34592759"></a>Yeh J, Whited L, Saliba RM, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. <i>Blood Adv</i>. 2021;5(24):5599-5607. doi:10.1182/bloodadvances.2021004846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/34592759/pubmed" id="34592759" target="_blank">34592759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26178288">
<a name="26178288"></a>Yilmaz N, Emmungil H, Gucenmez S, et al. Incidence of cyclophosphamide-induced urotoxicity and protective effect of Mesna in rheumatic diseases. <i>J Rheumatol</i>. 2015;42(9):1661-1666. doi:10.3899/jrheum.150065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/26178288/pubmed" id="26178288" target="_blank">26178288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30760451">
<a name="30760451"></a>Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. <i>Blood</i>. 2019;133(16):1720-1728. doi:10.1182/blood-2018-11-884577<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cyclophosphamide-pediatric-drug-information/abstract-text/30760451/pubmed" id="30760451" target="_blank">30760451</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13191 Version 480.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
